Home Cart Sign in  
Chemical Structure| 918504-65-1 Chemical Structure| 918504-65-1

Structure of Vemurafenib
CAS No.: 918504-65-1

Chemical Structure| 918504-65-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Vemurafenib (PLX4032) is a first-in-class, selective, and potent inhibitor of B-RAF kinase, with IC50s of 31 nM for RAFV600E and 48 nM for c-RAF-1. Vemurafenib induces cell autophagy.

Synonyms: PLX4032; RG7204; RO5185426

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Foda, Bardees ; Baker, Annika ; Joachimiak, Lukasz ; Mazur, Marzena ; Neubig, Richard Rick ;

Abstract: Aim: Overcoming therapy resistance is critical for effective melanoma control. Upregulation of Rho/MRTF signaling in human and mouse melanomas causes resistance to targeted therapies. Inhibition of this pathway by MRTFi, CCG-257081 resensitized resistant melanomas to BRAF and inhibitors. It also prevented the development of resistance to (Vem). Here, we investigate the role of and the protein pirin in CCG-257081-mediated suppression of drug resistance. Methods: Using naïve and resistant mouse YUMMER melanoma cells, we studied the effect of the BRAF inhibitor Vem with or without CCG-257081 on real-time growth and (activation of , (PI) staining, and cleavage). The effects of CCG-257081 on proliferation (Ki67) and caspase-3 activation were assessed in resistant YUMMER_R tumors in vivo. Finally, two CCG-257081 enantiomers were tested for binding, inhibition of the Rho/MRTF-mediated activation of ACTA2 gene expression in fibroblasts, and the prevention of Vem resistance development by YUMMER_P cells. Results: Vem reduced growth of parental but not resistant cells, while CCG-257081 inhibited both. The combination was more effective than Vem alone. CCG-257081, but not Vem, induced activation of caspase-3 and -7 in resistant cells and increased cleavage and staining. CCG-257081 reduced proliferation and activated caspase-3 in YUMMER_R melanoma tumors. Both CCG-257081 enantiomers robustly suppressed development of Vem-resistant colonies with the S isomer being more potent (1 µM IC50). Conclusion: CCG-257081 appears to target pre-resistant cells and Vem-induced resistant cells through enhanced . Inhibition of or the Rho/MRTF pathway can be employed to prevent melanoma resistance.

Keywords: Melanoma ; Resistance ; RhoGTPases ; caspases ; ; pirin

Purchased from AmBeed:

Foda, Bardees M. ; Neubig, Richard R. ;

Abstract: Cutaneous melanoma is the deadliest skin cancer. Most have Ras-MAPK pathway (BRAFV600E or NRAS) mutations and highly effective targeted therapies exist; however, they and immune therapies are limited by resistance, in part driven by small GTPase (Rho and Rac) activation. To facilitate preclin. studies of combination therapies to provide durable responses, we describe the first mouse melanoma lines resistant to BRAF inhibitors. Treatment of mouse lines, YUMM1.7 and YUMMER, with vemurafenib (Vem), the BRAFV600E-selective inhibitor, resulted in high-level resistance (IC50 shifts 20-30-fold). Resistant cells showed enhanced activation of Rho and the downstream transcriptional coactivator, myocardin-related transcription factor (MRTF). Resistant cells exhibited increased stress fibers, nuclear translocation of MRTF-A, and an increased MRTF-A gene signature. Pharmacol. inhibition of the Rho/MRTF pathway using CCG-257081 reduced viability of resistant lines and enhanced sensitivity to Vem. Remarkably, co-treatment of parental lines with Vem and CCG-257081 eliminated resistant colony development. Resistant cells grew more slowly in vitro, but they developed highly aggressive tumors with a shortened survival of tumor-bearing mice. Increased expression of immune checkpoint inhibitor proteins (ICIs) in resistant lines may contribute to aggressive in vivo behavior. Here, we introduce the first drug-resistant mouse melanoma models for assessing combinations of targeted and immune therapies.

Keywords: melanoma ; resistance ; immune checkpoint ; BRAF ; RhoGTPase

Purchased from AmBeed:

Alternative Products

Product Details of Vemurafenib

CAS No. :918504-65-1
Formula : C23H18ClF2N3O3S
M.W : 489.92
SMILES Code : CCCS(=O)(NC1=CC=C(F)C(C(C2=CNC3=NC=C(C4=CC=C(Cl)C=C4)C=C32)=O)=C1F)=O
Synonyms :
PLX4032; RG7204; RO5185426
MDL No. :MFCD18074504
InChI Key :GPXBXXGIAQBQNI-UHFFFAOYSA-N
Pubchem ID :42611257

Safety of Vemurafenib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Vemurafenib

MAPK

Isoform Comparison

Biological Activity

Target
  • B-Raf

    B-Raf, IC50:100 nM

    B-Raf (V600E), IC50:31 nM

  • C-Raf/Raf-1

    C-Raf, IC50:48 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
SK-Mel-19R 2 μM 2 months To select vemurafenib-resistant melanoma cell lines and analyze the activation of the RhoA signaling pathway. PMC7024013
UACC62R 2 μM 2 months To select vemurafenib-resistant melanoma cell lines and analyze the activation of the RhoA signaling pathway. PMC7024013
K-1 10 μM 24 h To evaluate the antitumor effect of Vemurafenib on K-1 cells, results showed that E3330 could enhance the antitumor effect of vemurafenib. PMC8825860
BCPAP 10 μM 24 h To evaluate the antitumor effect of Vemurafenib on BCPAP cells, results showed that E3330 could enhance the antitumor effect of vemurafenib. PMC8825860
HT29 cells 10 µM 12 h To evaluate the inhibitory effect of Vemurafenib on TSZ-induced necroptotic cell death, results showed that Vemurafenib significantly inhibited necroptotic cell death. PMC10449909
MDF cells 10 µM 6 h To evaluate the inhibitory effect of Vemurafenib on TSZ-induced necroptotic cell death, results showed that Vemurafenib significantly inhibited necroptotic cell death. PMC10449909
L929 cells 10 µM 24 h To evaluate the inhibitory effect of Vemurafenib on TNFα-induced necroptotic cell death, results showed that Vemurafenib significantly inhibited necroptotic cell death. PMC10449909

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Xenogeneic subcutaneous tumor model Oral 20 mg/kg Once daily for 21 days To evaluate the inhibitory effect of combined treatment with Vemurafenib and E3330 on xenogeneic subcutaneous tumors, results showed that the combined treatment significantly inhibited tumor growth and progression. PMC8825860
C57BL/6 mice LPS/z-VAD-induced macrophage necroptosis model Intraperitoneal injection 5 mg/kg 15 mins pretreatment To evaluate the inhibitory effect of Vemurafenib on LPS/z-VAD-induced macrophage necroptosis, results showed that Vemurafenib significantly inhibited macrophage necroptosis and reduced the secretion of proinflammatory cytokines. PMC10449909
Mice Melanoma model Intraperitoneal injection 1 mg/kg Daily for one week PLX4032 inhibits melanoma metastasis by suppressing integrin signaling through PGC1α and ID2 PMC5161587

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02052193 Metastatic Melanoma (Carrying ... More >>BRAF V600 Mutation) Less << Phase 2 Terminated(Second cohort not o... More >>pened because Simon-Two_Step model failed) Less << December 2017 Germany ... More >> Department of Dermatology Tuebingen, BW, Germany, 72076 Less <<
NCT01603212 Melanoma Phase 1 Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03139513 - Active, not recruiting December 31, 2018 France ... More >> Centre Hospitalier d'Albi Albi Cedex 9, France, 81013 Hopital Prive D Antony; Dermatologie Antony, France, 92166 Chic Cote Basque Bayonne; Medecine II Bayonne, France, 64109 CHU Besançon - Hôpital Jean Minjoz Besançon Cedex, France, 25030 Hopital Avicenne; Dermatologie Bobigny, France, 93009 CH Fleyriat Bourg en Bresse, France, 01000 CH Metropole de Savoie CHAMBERY Cedex, France, 73011 Chu Estaing; Dermatologie Clermont Ferrand, France, 63003 Hopital Louis Pasteur; Sce Dermatologie Colmar, France, 68024 Centre Georges Francois Leclerc Dijon, France, 21000 Chu Site Du Bocage;Dermatologie Dijon, France, 21079 Centre Hospitalier Le Mans; Dermatologie Le Mans, France, 72037 Hopital Claude Huriez; Sce Dermatologie Lille, France, 59037 CHU de Limoges - Hôpital Dupuytren Limoges, France, 87042 Hopital Timone Adultes; Dermatologie Marseille, France, 13385 Hopital Jacques Monod; Dermatologie Montivilliers, France, 76290 Hopital Saint Eloi; CHU de Montpellier; Svc de Dermatologie Montpellier, France, 34295 CH de Mulhouse Hôpital Emile Muller Mulhouse, France, 68070 Hopital l Archet 2; Ginestriere, Service de; Dermatologie Nice cedex 3, France, 06200 Hopital Cochin; Dermatologie Paris, France, 75006 Groupe Hospitalier Bichat Claude Bernard Paris, France, 75018 CENTRE HOSPITALIER ANNECY-GENEVOIS; Dematologie Pringy, France Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer Rennes, France, 35000 CHU Rouen - CH C. Nicolle - Clinique dermatologique Rouen, France, 76031 CHU de Saint-Etienne - Hopital Nord Saint Etienne, France, 42055 CHI de Poissy St Germain Saint Germain, France, 07810 Hopital Broussais St Malo Cedex, France, 35403 Pole de Cancerologie Prive Strasbourgeois Strasbourg, France, 67000 Hopital Bel Air Thionville Cedex, France, 57126 Hia Sainte Anne; Medecine Interne Oncologie Toulon, France, 83041 CHU de Toulouse - Hôpital Larrey Toulouse, France, 31059 Centre Hospitalier Valence Valence, France, 26953 Institut Gustave Roussy; Dermatologie Villejuif, France, 94805 Less <<
NCT03543969 Melanoma (Skin) ... More >> Skin Cancer Skin Melanoma Skin Carcinoma Less << Early Phase 1 Recruiting September 2021 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Leticia Tetteh    813-745-4617    leticia.tetteh@moffitt.org    Principal Investigator: Zeynep Eroglu, M.D. Less <<
NCT03101254 Melanoma Phase 1 Phase 2 Recruiting October 30, 2023 United States, Massachusetts ... More >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Elizabeth Buchcinder, MD    617-632-5055       Principal Investigator: Elizabeth Buchbinder, MD Less <<
NCT01659151 Metastatic Melanoma Phase 2 Active, not recruiting December 2019 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT01974258 Neoplasms Phase 1 Withdrawn July 2014 United States, California ... More >> Los Angeles, California, United States, 90025 United States, Florida Sarasota, Florida, United States, 34232 United States, Michigan Detroit, Michigan, United States, 48201 United States, Ohio Canton, Ohio, United States, 44718 United States, Oklahoma Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Nashville, Tennessee, United States, 37203 Less <<
NCT00405587 Malignant Melanoma|Colorectal ... More >>Carcinoma Less << PHASE1 COMPLETED 2025-02-16 University of California Los A... More >>ngeles, Los Angeles, California, 90095, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, 37232, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Peter MacCallum Cancer Centre, East Melbourne, Victoria, 3002, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia Less <<
NCT02902029 Malignant Melanoma Phase 2 Recruiting December 2021 France ... More >> Hôpital Ambroise-Paré Recruiting Boulogne-Billancourt, France, 92104 Contact: Philippe Saiag, Prof.       philippe.saiag@apr.aphp.fr    Hospital Claude Huriez Not yet recruiting Lille, France, 59000 Contact: Laurent Mortier, Prof.       laurent.mortier@chru-lille.fr    Hôpital de la Timone Recruiting Marseille, France, 13885 Contact: Jean J Grob, Prof.       jean-jacques.grob@ap-hm.fr    CHU de Nantes Not yet recruiting Nantes, France, 44093 Contact: Brigitte Dreno, Prof.       brigitte.dreno@wanadoo.fr    Centre Hospitalier Lyon Sud Not yet recruiting Pierre-Bénite, France, 69310 Contact: Stéphane Dalle, Dr.       stephane.dalle@chu-lyon.fr    Germany SLK-Kliniken Heilbronn GmbH Recruiting Heilbronn, Baden-Wuerttemberg, Germany, 74078 Contact: Uwe Martens, Prof. Dr.       uwe.martens@slk-kliniken.de    Principal Investigator: Uwe Martens, Prof. Dr.          Sub-Investigator: Jamil Akkad          University Hospital Mannheim, Clinic for Dermatology Recruiting Mannheim, Baden-Wuerttemberg, Germany, 68167 Contact: Jochen Utikal, Prof. Dr.       jochen.utikal@umm.de    Principal Investigator: Jochen Utikal, Prof. Dr.          Sub-Investigator: Maria Rita Gaiser, PD Dr. med.          National Centre for Tumour Diseases (NCT) Recruiting Heidelberg, BW, Germany, 69120 Contact: Jessica Hassel, Dr. med.       jessica.hassel@med.uni-heidelberg.de    Principal Investigator: Jessica Hassel, Dr. med.          Sub-Investigator: Martin Hartmann, Dr. med          University Hospital Essen, Department of Dermatology, Skin Cancer Center Recruiting Essen, North Rhine-Westphalia, Germany, 45122 Contact: Dirk Schadendorf, Prof. Dr.       dirk.schadendorf@uk-essen.de    Principal Investigator: Dirk Schadendorf, Prof. Dr.          Sub-Investigator: Elisabeth Livingstone, Dr.          Sub-Investigator: Lisa Zimmer, Dr.          HELIOS Klinikum Erfurt Recruiting Erfurt, Thuringia, Germany, 99089 Contact: Rudolf Herbst, Prof. Dr.       rudolf.herbst@helios-kliniken.de    Principal Investigator: Rudolf Herbst, Prof. Dr.          Sub-Investigator: Ivonne Kellner, Dr. med.          Charité-Universitätsmedizin Berlin Recruiting Berlin, Germany, 10117 Contact: Felix Kiecker, Dr. med.       felix.kiecker@charite.de    Principal Investigator: Felix Kiecker, Dr. med.          Sub-Investigator: Claas Ulrich, Dr. med.          Elbe Kliniken Stade - Buxtehude Not yet recruiting Buxtehude, Germany, 21614 Contact: Peter Mohr, Dr. med.       Peter.Mohr@elbekliniken.de    Principal Investigator: Peter Mohr, Dr. med.          Universitätsklinik Dresden Recruiting Dresden, Germany, 01307 Contact: Friedegund Meier, Prof. Dr.       friedegund.meier@uniklinikum-dresden.de    Principal Investigator: Friedegund Meier, Prof. Dr.          Sub-Investigator: Marlene Garzarolli          Medizinische Hochschule Hannover Recruiting Hannover, Germany, 30625 Contact: Ralf Gutzmer, Prof. Dr.       gutzmer.ralf@mh-hannover.de    Principal Investigator: Ralf Gutzmer, Prof. Dr.          Sub-Investigator: Imke Satzger, Pd Dr.          Universitätsklinikum des Saarlandes Not yet recruiting Homburg/Saar, Germany, 66421 Contact: Claudia Pföhler, Prof. Dr.       Claudia.Pfoehler@uniklinikum-saarland.de    Principal Investigator: Claudia Pföhler, Prof. Dr.          Sub-Investigator: Thomas Vogt, Prof. Dr.          Universitäts-Hautklinik Kiel Recruiting Kiel, Germany, 24105 Contact: Katharina Kähler, Dr. med.       kckaehler@yahoo.de    Principal Investigator: Katharina Kähler, Dr. med.          Sub-Investigator: Axel Hauschild, Prof. Dr.          Universitätsklinikum Köln Not yet recruiting Köln, Germany, 50937 Contact: Cornelia Mauch, Prof. Dr.       cornelia.mauch@uk-koeln.de    Principal Investigator: Cornelia Mauch, Prof. Dr.          Universitätsklinikum Leipzig Recruiting Leipzig, Germany, 04103 Contact: Jan Christoph Simon, Prof. Dr.       jan.simon@medizin.uni-leipzig.de    Principal Investigator: Jan Christoph Simon, Prof. Dr.          Sub-Investigator: Mirjana Ziemer, Dr. med.          Gesellschaft für Klinische Forschung Ludwigshafen mbH Recruiting Ludwigshafen, Germany, 67063 Contact: Edgar Dippel, Prof. Dr.       dippele@klilu.de    Principal Investigator: Edgar Dippel, Prof. Dr.          Sub-Investigator: Evelyn Dabrowski, Dr. med.          Universitätsklinikum Schleswig-Holstein Recruiting Lübeck, Germany, 23538 Contact: Patrick AM Terheyden, PD Dr. med.       patrick.terheyden@uksh.de    Principal Investigator: Patrick AM Terheyden, PD Dr. med.          Sub-Investigator: Diamant Thaci, Prof.          Universitätsklinikum Mainz Recruiting Mainz, Germany, 55131 Contact: Carmen Loquai, Prof. Dr.       carmen.loquai@unimedizin-mainz.de    Principal Investigator: Carmen Loquai, Prof. Dr.          Sub-Investigator: Stephan Grabbe, Prof. Dr.          Sub-Investigator: Heidrun Karin Mitzel-Rink, Dr.          Johannes Wesling Klinikum Minden Recruiting Minden, Germany, 32429 Contact: Rudolf Stadler, Prof. Dr.       rudolf.stadler@muehlenkreiskliniken.de    Principal Investigator: Rudolf Stadler, Prof. Dr.          Sub-Investigator: Jörg Böttjer, Dr.          Klinikum der Universität München Recruiting München, Germany, 80337 Contact: Carola Berking, Prof. Dr.       Carola.Berking@med.uni-muenchen.de    Principal Investigator: Carola Berking, Prof. Dr.          Sub-Investigator: Julia Katharina Tietze, Dr. med.          Universitätsklinikum Tübingen Recruiting Tübingen, Germany, 72076 Contact: Claus Garbe, Prof. Dr.       claus.garbe@med.uni-tuebingen.de    Principal Investigator: Claus Garbe, Prof. Dr.          Sub-Investigator: Thomas Kurt Eigentler, PD Dr. med.          Sub-Investigator: Benjamin Matthias Weide, Dr. med.          Uniklinikum Würzburg Recruiting Würzburg, Germany, 97080 Contact: Anja Heike Gesierich, MD       Gesierich_A@ukw.de    Principal Investigator: Anja Heike Gesierich, MD          Sub-Investigator: Marion Wobser, Dr.          Greece "LAIKO" General Hospital of Athens Recruiting Athens, Greece, 11527 Contact: Helen Gogas, Prof.       hgogas@hol.gr    Serbia Military Medical Academy Recruiting Belgrad, Serbia, 11000 Contact: Lidija Kandolf-Sekulovic, Prof.       lkandolfsekulovic@gmail.com Less <<
NCT00405587 Malignant Melanoma|Colorectal ... More >>Carcinoma Less << PHASE1 COMPLETED 2025-02-16 University of California Los A... More >>ngeles, Los Angeles, California, 90095, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, 37232, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Peter MacCallum Cancer Centre, East Melbourne, Victoria, 3002, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia Less <<
NCT02077114 Malignant Melanoma With Metast... More >>asis Less << Phase 1 Completed - Denmark ... More >> Department of Oncology, Herlev Hospital Herlev, Denmark, 2730 Less <<
NCT01897116 Melanoma Phase 1 Completed - United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT02089724 - Recruiting April 2019 United States, New York ... More >> Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Eli L. Diamond, MD, PhD       diamonel@mskcc.org    Principal Investigator: Eli L. Diamond, MD, PhD          Sub-Investigator: Omar Abdel-Wahab, MD          France AP-HP, Groupe Hospitalier Pitié-Salpêtrière Recruiting Paris, France, 75013 Contact: Julien Haroche, MD, PhD    +33 1 42 17 80 37    julien.haroche@psl.aphp.fr    Contact: Fleur Cohen Aubart, MD, PhD    +33 1 42 17 82 42    fleur.cohen@psl.aphp.fr    Principal Investigator: Julien Haroche, MD, PhD          Sub-Investigator: Fleur Cohen Aubart, MD, PhD          Sub-Investigator: Zahir Amoura, MD, MSc Less <<
NCT03224767 BRAF V600E Mutation Present ... More >> Papillary Craniopharyngioma Less << Phase 2 Recruiting August 2026 -
NCT03013491 Solid Tumor L... More >>ymphoma Less << Phase 1 Phase 2 Recruiting December 2021 -
NCT01656642 Malignant Melanoma Phase 1 Active, not recruiting November 28, 2018 United States, California ... More >> UCLA Los Angeles, California, United States, 90024 The Angeles Clinic and Research Institute - W LA Office Los Angeles, California, United States, 90025 United States, Colorado University of Colorado Health Science Center; Biomedical Research Bldg. Room 511 Aurora, Colorado, United States, 80045 United States, Florida Florida Cancer Specialists - Sarasota Sarasota, Florida, United States, 34232 Florida Cancer Specialists West Palm Beach, Florida, United States, 33401 United States, Massachusetts Massachusetts General Hospital. Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Med Ctr Boston, Massachusetts, United States, 02215 Dana Farber Can Ins Boston, Massachusetts, United States, 02215 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03108209 Phototoxicity Not Applicable Recruiting October 2017 France ... More >> CHU Nantes Recruiting Nantes, France Contact: Aurélie BOISROBERT          Contact    02.40.08.31.22 Less <<
NCT03514901 Melanoma Metastatic ... More >> BRAF V600 Mutation Less << Phase 2 Not yet recruiting April 3, 2021 Italy ... More >> Istituto dei Tumori "Giovanni Paolo II" Not yet recruiting Bari, BA, Italy, 70124 Contact: Michele Guida, Dr.          ASST Papa Giovanni XXIII Not yet recruiting Bergamo, BG, Italy, 24127 Contact: Mario Mandalà, Dr.          Policlinico Sant'Orsola Malpighi Not yet recruiting Bologna, BO, Italy, 40138 Contact: Barbara Melotti, Dr.          IRCCS IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Not yet recruiting Meldola, FC, Italy, 47014 Contact: Massimo Guidoboni, Dr.          Ospedale Policlinico San Martino Active, not recruiting Genova, GE, Italy, 16132 P.O. di Taormina - Azienda Sanitaria Provinciale di Messina Not yet recruiting Taormina, ME, Italy, 98039 Contact: Francesco Ferraù, Dr.          Fondazione IRCCS Istituto Nazionale dei Tumori Not yet recruiting Milano, MI, Italy, 20133 Contact: Michele Del Vecchio, Dr.          Istituto Oncologico Veneto - IRCCS Not yet recruiting Padova, PD, Italy, 35128 Contact: Vanna Chiarion Sileni, Dr.          Ospedale S. Chiara - A.O.U. Pisana Not yet recruiting Pisa, PI, Italy, 56125 Contact: Alfredo Falcone, Prof.          A.O.U.S. Policlinico "Le Scotte" Not yet recruiting Siena, SI, Italy, 53100 Contact: Anna Maria Di Giacomo, Dr.          P.O. San Lazzaro - A.O.U. Città della Salute e della Scienza di Torino - Molinette Not yet recruiting Torino, TO, Italy, 10126 Contact: Maria Teresa Fierro, Prof.          Istituti Fisioterapici Ospitalieri - IFO - Istituto "Regina Elena" Not yet recruiting Roma, Italy, 00144 Contact: Virginia Ferraresi, Dr.          IDI Istituto Dermopatico Immacolata Not yet recruiting Roma, Italy, 00167 Contact: Alessandro Scoppola, Dr. Less <<
NCT01585415 Metastatic Cancer ... More >> Melanoma Less << Phase 1 Terminated - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01597908 - Active, not recruiting - -
NCT01841463 Advanced or Inoperable Maligna... More >>nt Melanoma With BRAF Mutation Less << Phase 1 Suspended(Sponsor decision not... More >> related to patient safety) Less << March 2016 United States, California ... More >> UCSF Medical Center at Mount Zion South San Francisco, California, United States, 94115 United States, Colorado University of Colorado Anschutz Medical Campus Aurora, Colorado, United States, 80045 United States, District of Columbia Georgetown-Lombardi Comprehensive Cancer Ctr Washington, District of Columbia, United States, 20057 United States, Texas The University of Texas, MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00949702 Malignant Melanoma Phase 2 Completed - United States, California ... More >> UCLA - School of Medicine; Division of Hematology/Oncology Los Angeles, California, United States, 90095-6984 United States, Colorado University of Colorado Denver, Colorado, United States, 80262 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Massachusetts Massachusetts General Hospital;Hematology/ Oncology Boston, Massachusetts, United States, 02114 Dana Farber Cancer Inst. ; Dept. of Medical Oncology Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 United States, New York New York University Medical Center New York, New York, United States, 10036 United States, Pennsylvania Hospital of the Uni of Pennsylvania; Section of Hematology/Oncology Philadelphia, Pennsylvania, United States, 19104-4283 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee Vanderbilt-Ingram Cancer Ctr Nashville, Tennessee, United States, 37232 United States, Texas Texas Oncology-Baylor Sammons Cancer Center Dallas, Texas, United States, 75246 University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Australia, New South Wales Calvary Mater Newcastle; Melanoma Clinic Newcastle, New South Wales, Australia, 2298 Westmead Hospital; Medical Oncology and Pallative Care Westmead, New South Wales, Australia, 2145 Australia, Victoria Peter Maccallum Cancer Institute; Medical Oncology Melbourne, Victoria, Australia, 3000 Less <<
NCT01597908 Melanoma Phase 3 Active, not recruiting March 18, 2019 -
NCT00949702 - Completed - -
NCT02908672 Melanoma Phase 3 Active, not recruiting July 29, 2023 -
NCT01512251 - Completed - -
NCT01378975 Malignant Melanoma PHASE2 COMPLETED 2025-07-15 Los Angeles, California, 90025... More >>, United States|Aurora, Colorado, 80045, United States|Tampa, Florida, 33612-9497, United States|Boston, Massachusetts, 02114, United States|Boston, Massachusetts, 02215, United States|Detroit, Michigan, 48201, United States|Rochester, Minnesota, 55905, United States|Saint Louis, Missouri, 63110, United States|Charlotte, North Carolina, 28204-2839, United States|Dallas, Texas, 75246, United States|Seattle, Washington, 98195, United States|Wentworthville, New South Wales, 2145, Australia|Melbourne, Victoria, 3002, Australia|Toronto, Ontario, M4N 3M5, Canada|Bordeaux, 33075, France|Nice, 06202, France|Paris, 75006, France|Paris, 75475, France|Essen, 45122, Germany|Frankfurt, 60596, Germany|Kiel, 24105, Germany|Mannheim, 68167, Germany|Münster, 48157, Germany|Tübingen, 72076, Germany|Tel-Hashomer, 52621, Israel|Milano, Lombardia, 20133, Italy|Siena, Toscana, 53100, Italy|Amsterdam, 1066 CX, Netherlands|Groningen, 9713 GZ, Netherlands|Pamplona, Navarra, 31008, Spain|Barcelona, 08036, Spain|Madrid, 28046, Spain|Northwood, HA6 2RN, United Kingdom Less <<
NCT02164916 Colorectal Cancer Phase 2 Active, not recruiting January 2020 -
NCT01849666 Malignant Melanoma, Neoplasms Phase 1 Completed - Belgium ... More >> Brussels, Belgium, 1000 Edegem, Belgium, 2650 Gent, Belgium, 9000 Wilrijk, Belgium, 2610 Finland Helsinki, Finland, 00180 Germany Heidelberg, Germany, 69120 Mainz, Germany, 55101 Netherlands Amsterdam, Netherlands, 1066 CX Maastricht, Netherlands, 6229HX Utrecht, Netherlands, 3584 CX Spain Pamplona, Navarra, Spain, 31008 Barcelona, Spain, 08908 Madrid, Spain, 280146 Madrid, Spain, 28031 Madrid, Spain, 28040 Madrid, Spain, 28041 Madrid, Spain, 28050 Less <<
NCT03727763 Colorectal Cancer Phase 2 Recruiting December 31, 2020 China, Shanghai ... More >> Shanghai Changzheng Hospital Recruiting Shanghai, Shanghai, China, 200433 Contact: Zhan Wang, Prof.    +8613916229609    profoundamir@139.com Less <<
NCT01378975 Malignant Melanoma PHASE2 COMPLETED 2025-07-15 Los Angeles, California, 90025... More >>, United States|Aurora, Colorado, 80045, United States|Tampa, Florida, 33612-9497, United States|Boston, Massachusetts, 02114, United States|Boston, Massachusetts, 02215, United States|Detroit, Michigan, 48201, United States|Rochester, Minnesota, 55905, United States|Saint Louis, Missouri, 63110, United States|Charlotte, North Carolina, 28204-2839, United States|Dallas, Texas, 75246, United States|Seattle, Washington, 98195, United States|Wentworthville, New South Wales, 2145, Australia|Melbourne, Victoria, 3002, Australia|Toronto, Ontario, M4N 3M5, Canada|Bordeaux, 33075, France|Nice, 06202, France|Paris, 75006, France|Paris, 75475, France|Essen, 45122, Germany|Frankfurt, 60596, Germany|Kiel, 24105, Germany|Mannheim, 68167, Germany|Münster, 48157, Germany|Tübingen, 72076, Germany|Tel-Hashomer, 52621, Israel|Milano, Lombardia, 20133, Italy|Siena, Toscana, 53100, Italy|Amsterdam, 1066 CX, Netherlands|Groningen, 9713 GZ, Netherlands|Pamplona, Navarra, 31008, Spain|Barcelona, 08036, Spain|Madrid, 28046, Spain|Northwood, HA6 2RN, United Kingdom Less <<
NCT01765556 Malignant Melanoma, Neoplasms Phase 1 Withdrawn October 2013 -
NCT01843738 BRAFV600 Mutation ... More >> Stage IV Melanoma Less << Phase 1 Withdrawn(Competing Trials) August 2022 United States, Utah ... More >> Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Less <<
NCT02414750 Metastatic Melanoma Phase 2 Recruiting December 2018 Netherlands ... More >> The Netherlands Cancer Institute Recruiting Amsterdam, Netherlands, 1066CX Contact: Bernies Van der Hiel, MD    +31205126129    b.vd.hiel@nki.nl    Principal Investigator: John B.A.G. Haanen, Prof.          VU medical center Recruiting Amsterdam, Netherlands Contact: Fons J.M. Van den Eertwegh, MD PhD    +31204444336    vandeneertwegh@vumc.nl    Principal Investigator: Fons J.M. Van den Eertwegh, MD PhD          Medisch Spectrum Twente Not yet recruiting Enschede, Netherlands Contact: D. Piersma, MD PhD       d.piersma@mst.nl    Principal Investigator: D. Piersma, MD PhD          University Medical Center Groningen Recruiting Groningen, Netherlands Contact: G. A.P. Hospers, Prof.       g.a.p.hospers@umcg.nl    Principal Investigator: G. A.P. Hospers, Prof.          Leiden University Medical Center Recruiting Leiden, Netherlands Contact: H. W. Kapiteijn, MD PhD       h.w.kapiteijn@lumc.nl    Principal Investigator: H. W. Kapiteijn, MD PhD          Maastricht University Medical Center Recruiting Maastricht, Netherlands Contact: M. J.B. Aarts, MD       mjb.essers.aarts@mumc.nl    Principal Investigator: M. J.B. Aarts, MD          University Medical Center St Radboud Recruiting Nijmegen, Netherlands Contact: R. H.T. Koornstra, MD       r.koornstra@onco.umcn.nl    Principal Investigator: R. H.T. Koornstra, MD          Erasmus Medical Center Recruiting Rotterdam, Netherlands Contact: W. H.J. Kruit, MD PhD       w.kruit@erasmusmc.nl    Principal Investigator: W. H.J. Kruit, MD PhD          University Medical Center Utrecht Recruiting Utrecht, Netherlands Contact: F. Y.F.L. de Vos, MD PhD       f.devos@umcutrecht.nl    Principal Investigator: F. Y.F.L. de Vos, MD PhD          Isala Klinieken Recruiting Zwolle, Netherlands Contact: J. W.B. de Groot, MD PhD       j.w.b.de.groot@isala.nl    Principal Investigator: J. W.B. de Groot, MD PhD Less <<
NCT01271803 Malignant Melanoma Phase 1 Completed - United States, California ... More >> UCLA Department of Medicine Los Angeles, California, United States, 90024 University of California at San Francisco San Francisco, California, United States, 94115 The Angeles Clinic and Research Institute, Santa Monica Office Santa Monica, California, United States, 90025 United States, Colorado University of Colorado; Anschutz Cancer Pavilion Aurora, Colorado, United States, 80045 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Indiana Indiana University - Department of Medicine, Division of Gastroenterology/Hepatology Indianapolis, Indiana, United States, 46202 United States, Michigan Karmanos Cancer Inst. ; Hudson Webber; Cancer Research Building Detroit, Michigan, United States, 48201 United States, New York New York University Medical Center New York, New York, United States, 10036 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 Australia, Victoria Peter Maccallum Cancer Institute; Medical Oncology Melbourne, Victoria, Australia, 3000 Less <<
NCT02164916 - Active, not recruiting - -
NCT01909453 Melanoma Phase 3 Active, not recruiting March 31, 2019 -
NCT01512251 BRAF Mutant Metastatic Melanom... More >>a Less << Phase 1 Phase 2 Completed - United States, California ... More >> University of California, San Francisco San Francisco, California, United States, 94115 Less <<
NCT02583516 Melanoma Phase 2 Active, not recruiting September 2019 Spain ... More >> Hospital Universitario Donostia Donostia - San Sebastián, Guipuzcoa, Spain Hospital General Universitario Santa Lucía Cartagena, Murcia, Spain Hospital Clínic de Barcelona Barcelona, Spain Hospital del Mar Barcelona, Spain Hospital Universitario Vall d'Hebron Barcelona, Spain Hospital Insular de Gran Canaria Las Palmas de Gran Canaria, Spain Hospital Universitario Lucus Augusti Lugo, Spain Hospital Universitario 12 de Octubre Madrid, Spain Hospital Universitario La Paz Madrid, Spain Hospital Regional Universitario de Málaga Málaga, Spain Hospital Clínico Universitario de Salamanca Salamanca, Spain Hospital Universitario Virgen Macarena Sevilla, Spain Hospital Universitario de Canarias Tenerife, Spain Hospital General Universitario de Valencia Valencia, Spain Hospital Universitario Doctor Peset Valencia, Spain Hospital Universitario y Politécnico La Fe Valencia, Spain Hospital Álvaro Cunqueiro (Complejo Hospitalario Universitario de Vigo) Vigo, Spain Hospital Universitario Miguel Servet Zaragoza, Spain Less <<
NCT02608034 Metastatic Melanoma, BRAF V600... More >> Mutation Positive Less << Phase 1 Active, not recruiting January 8, 2019 United States, Kansas ... More >> University of Kansas Cancer Center and Medical Pavilion Westwood, Kansas, United States, 66205 United States, Texas Mary Crowley Medical Research Center Dallas, Texas, United States, 75230 Israel Rambam Health Care Campus; Oncology Haifa, Israel, 3109601 Hadassah Ein Karem Hospital; Oncology Dept Jerusalem, Israel, 9112001 Tel Aviv Sourasky Medical Center Tel Aviv, Israel, 64239 Korea, Republic of Seoul National University Hospital Seoul, Korea, Republic of, 03080 Samsung Medical Center; Gastroenterology Seoul, Korea, Republic of, 135-710 Asan Medical Center; Division of Oncology Seoul, Korea, Republic of, 138-736 Severance Hospital - Yonsei Uni ; Obstetrics & Gynaecology Dept. Seoul, Korea, Republic of Russian Federation Republican Clinical Oncologic Dispensary of Republic Of Tatarstan Kazan, Russian Federation, 420029 FSBSI "N. N. Blokhin Russian Cancer Research Center" Moscow, Russian Federation, 115478 St. Petersburg Oncology Hospital St Petersburg, Russian Federation, 198255 Less <<
NCT01531361 Advanced Malignant Neoplasm ... More >> BRAF Gene Mutation Metastatic Malignant Neoplasm Recurrent Malignant Neoplasm Refractory Malignant Neoplasm Less << Phase 1 Active, not recruiting February 28, 2020 United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01006980 Malignant Melanoma Phase 3 Completed - -
NCT01844674 Malignant Melanoma, Neoplasms Phase 1 Completed - United States, California ... More >> Diablo Valley Oncology and Hematology Pleasant Hill, California, United States, 94523 United States, Michigan Karmanos Cancer Center Detroit, Michigan, United States, 48201 United States, North Carolina Duke University Health Systems Durham, North Carolina, United States, 27710 Brazil Instituto Nacional do Cancer - INCA Rio de Janeiro, RJ, Brazil, 20560-120 Hospital de Caridade de Ijui; Oncologia Ijui, RS, Brazil, 98700-000 CITO - Centro Integrado de Terapia Onco-Hematológica - Hospital da Cidade de Passo Fundo Passo Fundo, RS, Brazil, 99010-260 Hospital Sao Lucas - PUCRS Porto Alegre, RS, Brazil, 90610-000 Canada, Quebec CSSS champlain - Charles-Le Moyne Greenfield Park, Quebec, Canada, J4V 2H1 Cyprus Bank of Cyprus Oncology Center Nicosia, Cyprus, 2006 Korea, Republic of Severance Hospital, Yonsei University Health System Seoul, Korea, Republic of, 03722 Samsung Medical Center Seoul, Korea, Republic of, 06351 Asan Medical Center. Seoul, Korea, Republic of, 138-736 Less <<
NCT01673737 Neoplasm Malignant Phase 1 Completed - United States, Massachusetts ... More >> Investigational Site Number 840001 Boston, Massachusetts, United States, 02114 Investigational Site Number 840101 Boston, Massachusetts, United States, 02115 United States, Texas Investigational Site Number 840002 Houston, Texas, United States, 77054 Canada Investigational Site Number 124001 Toronto, Canada, M5G 2M9 Less <<
NCT02354690 Metastatic Melanoma Phase 1 Phase 2 Active, not recruiting August 2020 Denmark ... More >> Center for Cancer Immune Therapy, Dept. of Haematology/Oncology Copenhagen, Herlev, Denmark, 2730 Less <<
NCT01271803 - Completed - -
NCT01006980 - Completed - -
NCT01898585 Malignant Melanoma Phase 4 Active, not recruiting December 10, 2019 South Africa ... More >> National Hospital; Oncotherapy Dept Bloemfontein, South Africa, 9301 Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept Cape Town, South Africa, 7506 Cape Town Oncology Trials Cape Town, South Africa, 7570 Cancercare Cape Town, South Africa, 7700 Cancercare George, South Africa, 6529 Mary Potter Oncology Centre Groenkloof, South Africa, 0181 Medical Oncology Centre of Rosebank; Oncology Johannesburg, South Africa, 2196 University of Pretoria; Department of Medical Oncology Pretoria, South Africa, 0002 Sandton Oncology Medical Group Sandton, South Africa, 2196 Less <<
NCT01787500 Advanced Cancers Phase 1 Active, not recruiting February 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01689519 Malignant Melanoma Phase 3 Active, not recruiting December 28, 2019 -
NCT02068079 Melanoma Phase 1 Withdrawn(Study is being revis... More >>ed) Less << - United States, North Carolina ... More >> Duke University Medical Center Durham, North Carolina, United States, 27710 Less <<
NCT01400451 Melanoma Phase 1 Terminated(More than 2 of 6 pa... More >>tients treated experienced dose limiting toxicities.) Less << - United States, California ... More >> University Of California Los Angeles Los Angeles, California, United States, 90095 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 Dana Farber Cancer Inst Boston, Massachusetts, United States, 02215 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01683188 Metastatic Melanoma Phase 4 Terminated(A shift in the mela... More >>noma treatment landscape adversely affected accrual & to early closure.) Less << - -
NCT01689519 - Active, not recruiting - -
NCT01765569 Malignant Melanoma, Neoplasms Phase 1 Completed - Belarus ... More >> Minsk District, Belarus, 223040 Minsk, Belarus, BU-220013 Vitebsk, Belarus, BU-210603 Israel Haifa, Israel, 31096 Tel Aviv, Israel, 6423906 Tel Hashomer, Israel, 52661 Korea, Republic of Daegu, Korea, Republic of, 702-911 Seoul, Korea, Republic of, 110-774 Seoul, Korea, Republic of, 135-710 Russian Federation Kazan, Russian Federation, 420029 Moscow, Russian Federation, 115478 St. Petersburg, Russian Federation, 197758 South Africa Johannesburg, South Africa, 2193 Less <<
NCT02968303 Melanoma, Malignant, of Soft P... More >>arts Less << Phase 2 Recruiting October 2023 Netherlands ... More >> The Netherlands Cancer Institute Not yet recruiting Amsterdam, Netherlands, 1066 CX Contact: Christian U Blank, Prof MD PhD    +31205129111    c.blank@nki.nl    Principal Investigator: Christian U Blank, Prof MD PhD          Radboudumc Recruiting Nijmegen, Netherlands, 6525GA Contact: Rutger HT Koornstra, MD    +31243610354    Rutger.Koornstra@radboudumc.nl    Contact: Peter van Essen, MSc    +31243655388    studies.onco@radboudumc.nl    Principal Investigator: Rutger HT Koornstra, MD          Isala Not yet recruiting Zwolle, Netherlands, 8025 AB Contact: Johannes WB de Groot, MD PhD    +31384245000    j.w.b.de.groot@isala.nl    Principal Investigator: Johannes WB de Groot, MD PhD Less <<
NCT01524978 Multiple Myeloma, Neoplasms Phase 2 Completed - -
NCT01524978 - Completed - -
NCT01400451 - Terminated(More than 2 of 6 pa... More >>tients treated experienced dose limiting toxicities.) Less << - -
NCT01765569 - Completed - -
NCT01673854 Melanoma Phase 2 Completed - United States, California ... More >> Beverly Hills Cancer Center Beverly Hills, California, United States, 90211 United States, Florida Baptist Cancer Institute Jacksonville, Florida, United States, 32207 Orlando Health, Inc Orlando, Florida, United States, 32806 United States, Georgia Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, New Mexico University Of New Mexico Cancer Center Albuquerque, New Mexico, United States, 87106 United States, New York Mount Sinai School Of Medicine New York, New York, United States, 10029 United States, North Carolina Levine Cancer Institute Charlotte, North Carolina, United States, 28204 Duke University Hospital Durham, North Carolina, United States, 27710 Dumc Durham, North Carolina, United States, 27710 United States, Ohio University Hospitals Of Cleveland Cleveland, Ohio, United States, 44106 University Hospitals Cleveland, Ohio, United States, 44106 Less <<
NCT01673854 - Completed - -
NCT01876641 Metastatic Melanoma ... More >> Melanoma BRAF-mutated Metastatic Melanoma V600EBRAF-mutated Metastatic Melanoma Less << Phase 1 Terminated(Loss of funding) - United States, Iowa ... More >> University of Iowa Hospitals & Clinics Iowa City, Iowa, United States, 52242 Less <<
NCT01826448 V600-mutated BRAF Unresectable... More >> Melanoma V600-mutated BRAF Metastatic Melanoma Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor Less << Phase 1 Terminated - United States, California ... More >> UCLA Los Angeles, California, United States, 90024 United States, Colorado University of Colorado, Denver Aurora, Colorado, United States, 80012 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 France Institute Gustave Roussy Paris, France Germany University Hospital Essen Essen, Germany Less <<
NCT03625141 Metastatic Melanoma Phase 2 Not yet recruiting March 29, 2023 France ... More >> CHRU de Lille - Hopital Claude Huriez Not yet recruiting Lille, France, 59037 CH Saint Eloi Not yet recruiting Montpellier, France, 34295 Nantes hospital, Hôtél_Dieu, Oncodermatology Not yet recruiting Nantes, France, 44093 Institut Claudius Regaud; Departement Oncologie Medicale Not yet recruiting Toulouse, France, 31059 Institut Gustave Roussy; Dermatologie Not yet recruiting Villejuif, France, 94805 Hungary Semmelweis Egyetem; Bor-, Nemikortani es Boronkologiai Klinika Not yet recruiting Budapest, Hungary, 1085 Orszagos Onkologiai Intezet; Borgyogyaszati Osztaly Not yet recruiting Budapest, Hungary, 1122 Pecsi Tudomanyegyetem AOK; Borgyogyaszati Klinika Not yet recruiting Pecs, Hungary, 7632 Less <<
NCT01657591 Melanoma Phase 1 Active, not recruiting June 2019 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT01835184 Recurrent Melanoma ... More >> Stage IIIA Melanoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Terminated - United States, Georgia ... More >> Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 Less <<
NCT02145143 Thyroid Carcinoma Not Applicable Active, not recruiting May 2019 United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01495988 - Terminated(Slow accrual; toxic... More >>ity; change in priorities) Less << - -
NCT01474551 - Terminated(Lack of accrual) - -
NCT01474551 Melanoma Phase 2 Terminated(Lack of accrual) - United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01495988 Melanoma Meta... More >>static Melanoma Less << Phase 2 Terminated(Slow accrual; toxic... More >>ity; change in priorities) Less << - United States, California ... More >> The Angeles Clinic Los Angeles, California, United States, 90025 United States, Colorado University of Colorado Cancer Center Aurora, Colorado, United States, 80045 United States, District of Columbia Georgetown Lombardi Comprehensive Cancer Center Washington, D.C., District of Columbia, United States, 20007 Washington Cancer Institute at MedStar Washington Hospital Center Washington, D.C., District of Columbia, United States, 20010 United States, Maryland Harry and Jeannette Weinberg Cancer Institute at Franklin Square Baltimore, Maryland, United States, 21237 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center (BIDMC) Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York NYU Clinical Cancer Center New York, New York, United States, 10016 Columbia University Medical Center New York, New York, United States, 10032 United States, Ohio OSU Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15232 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Washington University of Washington Medical Center Seattle, Washington, United States, 98109 Less <<
NCT01638676 Melanoma Phase 1 Phase 2 Recruiting June 2019 United States, Kentucky ... More >> James Graham Brown Cancer Center-University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Jason A Chesney, MD PhD    502-562-3429    jason.chesney@louisville.edu    Contact: Sarah Lush, RN    502-540-1537    s.lush@louisville.edu Less <<
NCT02721459 Melanoma Skin... More >> Cancer Less << Phase 1 Active, not recruiting December 2021 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT02145910 Recurrent Melanoma ... More >> Stage IV Melanoma Tumors Metastatic to Brain Less << Phase 1 Withdrawn(Study was never open... More >>ed to accrual. There is no clinical benefit to patients.) Less << - -
NCT03224208 Melanoma Mela... More >>noma (Skin) Melanoma Stage Less << Phase 2 Not yet recruiting March 2020 -
NCT03430947 Malignant Melanoma Stage IV ... More >> BRAF V600 Mutation Brain Metastases Less << Phase 2 Recruiting August 31, 2021 Germany ... More >> Technische Universität Dresden Recruiting Dresden, Germany, 01307 Contact: Friedegund Meier, MD    +49 351 458 ext 2497    friedegund.meier@uniklinikum-dresden.de    Contact: Esther Troost, MD    +49 351 458 ext 2394    esther.troost@uniklinikum-dresden.de    Principal Investigator: Friedegund Meier, MD          Principal Investigator: Esther Troost, MD, PhD          Ruprecht-Karls-University of Heidelberg, Faculty of Medicine Not yet recruiting Heidelberg, Germany, 69120 Contact: Jessica Hassel, MD          Eberhard Karls University of Tübingen, University Medical Center Not yet recruiting Tuebingen, Germany, 72076 Contact: Thomas Eigentler, MD Less <<
NCT01851824 Malignant Melanoma, Neoplasms Phase 1 Completed - Australia, New South Wales ... More >> Wodonga, New South Wales, Australia, 3690 Germany Buxtehude, Germany, 21614 Essen, Germany, 45122 Mannheim, Germany, 68167 Greece Crete, Greece, 71110 Thessaloniki, Greece, 56429 Hungary Budapest, Hungary, 1122 Netherlands Amsterdam, Netherlands, 1066 CX Maastricht, Netherlands, 6229HX Utrecht, Netherlands, 3584 CX New Zealand Auckland, New Zealand, 1142 Christchurch, New Zealand, 8011 Portugal Lisboa, Portugal, 1099-023 Porto, Portugal, 4200-072 Serbia Belgrade, Serbia, 11000 Spain Barcelona, Spain, 08036 Barcelona, Spain, 08908 Madrid, Spain, 28031 Madrid, Spain, 28040 Madrid, Spain, 28050 Less <<
NCT01286753 Neoplasms PHASE2 COMPLETED 2025-05-15 Torrance, California, 90502, U... More >>nited States|New Haven, Connecticut, 06510, United States|Chicago, Illinois, 60637, United States|Baltimore, Maryland, 21231, United States|Boston, Massachusetts, 02114, United States|Boston, Massachusetts, 02215, United States|New York, New York, 10017, United States|Philadelphia, Pennsylvania, 19104, United States|Houston, Texas, 77030, United States|Lyon, 69008, France|Paris, 75651, France|Villejuif, 94805, France|Milano, Lombardia, 20133, Italy|Pisa, Toscana, 56124, Italy|Groningen, 9700 RB, Netherlands|Leiden, 2300 RC, Netherlands Less <<
NCT03585686 Langerhans Cell Histiocytosis Phase 2 Recruiting December 2020 Russian Federation ... More >> Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology Recruiting Moscow, Russian Federation, 117997 Contact: Zhanna Shekhovtsova, MD    4956647078 ext 7538    zhanna.shekhovtsova@fccho-moscow.ru    Contact: Eugene Pashanov, PhD    +79262205578    e.pashanov@gmail.com    Sub-Investigator: Dmitry Evseev, MD          Principal Investigator: Michael Maschan, PhD Less <<
NCT01286753 Neoplasms PHASE2 COMPLETED 2025-05-15 Torrance, California, 90502, U... More >>nited States|New Haven, Connecticut, 06510, United States|Chicago, Illinois, 60637, United States|Baltimore, Maryland, 21231, United States|Boston, Massachusetts, 02114, United States|Boston, Massachusetts, 02215, United States|New York, New York, 10017, United States|Philadelphia, Pennsylvania, 19104, United States|Houston, Texas, 77030, United States|Lyon, 69008, France|Paris, 75651, France|Villejuif, 94805, France|Milano, Lombardia, 20133, Italy|Pisa, Toscana, 56124, Italy|Groningen, 9700 RB, Netherlands|Leiden, 2300 RC, Netherlands Less <<
NCT03220035 Advanced Malignant Solid Neopl... More >>asm Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma BRAF NP_004324.2:p.V600X Ependymoma Ewing Sarcoma Hepatoblastoma Histiocytosis Langerhans Cell Histiocytosis Malignant Germ Cell Tumor Malignant Glioma Osteosarcoma Peripheral Primitive Neuroectodermal Tumor Recurrent Childhood Central Nervous System Neoplasm Recurrent Childhood Non-Hodgkin Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Neuroblastoma Refractory Central Nervous System Neoplasm Refractory Malignant Solid Neoplasm Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Rhabdoid Tumor Rhabdomyosarcoma Soft Tissue Sarcoma Wilms Tumor Less << Phase 2 Recruiting December 31, 2023 -
NCT01667419 Melanoma Phase 3 Active, not recruiting October 14, 2020 -
NCT02303951 Malignant Melanoma Phase 2 Recruiting April 2020 France ... More >> Department of Dermatology & Skin Cancer University Hospital La Timone, Aix-Marseille University Recruiting Marseille, France, 13385 Contact: Jean-Jacque Grob, MD          Department of Dermatology, University Hospital of Nantes Recruiting Nantes, France, 44093 Contact: Brigitte Dreno, MD          Hopital Saint-Louis Hopitaux Universitaires Saint-Louis Laboisiere Fernand-Widal Recruiting Paris, France, 75010 Contact: Celeste Lebbé, MD          Germany Department of Dermatology, Elbe Hospital Recruiting Buxtehude, Germany, 21614 Contact: Peter Mohr, MD       Peter.Mohr@elbekliniken.de    Department of Dermatology, University Hospital Recruiting Kiel, Germany, 24105 Contact: Katharina C Kähler, MD       kkaehler@dermatology.uni-kiel.de    Department of Dermatology, University Hospital Recruiting Mainz, Germany, 55101 Contact: Carmen Loquai, MD       carmen.loquai@unimedizin-mainz.de    Contact: Stephan Grabbe, MD       hautklinik@unimedizin-mainz.de    University hospital Tübingen Recruiting Tübingen, Germany, 72076 Contact: Thomas Eigentler, Dr.    +49 7071 298 ext 5748    thomas.eigentler@med.uni-tuebingen.de    Contact: Claus Garbe, Prof.    +49 7071 298 ext 7110    claus.garbe@med.uni-tuebingen.de    Principal Investigator: Claus Garbe, Prof. Less <<
NCT02818023 Melanoma Phase 1 Recruiting October 2019 United States, Pennsylvania ... More >> UPMC Cancer Center Hillman Cancer Center Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Yana M. Najjar, MD    412-623-2294    najjaryg@upmc.edu    Contact: Amy Rose, RN, BSN    412-647-8587    kennaj@upmc.edu Less <<
NCT01611675 Melanoma Phase 1 Terminated(Adverse Events) - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT01636622 Advanced Cancers Phase 1 Active, not recruiting July 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03410875 Hairy Cell Leukemia ... More >> Leukemia Leukemia, Hairy Cell Less << Phase 2 Recruiting January 2020 United States, Connecticut ... More >> Yale University Not yet recruiting New Haven, Connecticut, United States, 06511 Contact: Gottfried von Keudell, MD/PhD    203-737-5312       United States, Massachusetts Dana Farber Cancer Institute Not yet recruiting Boston, Massachusetts, United States, 02115 Contact: Eric Winer, MD    617-632-6876       United States, New York Memorial Sloan - Kettering Cancer Center Recruiting New York, New York, United States, 10021 Contact: Jae Park, MD    212-639-4048    parkj6@mskcc.org Less <<
NCT01943422 Melanoma Phase 1 Completed - United States, Pennsylvania ... More >> Hillman Cancer Center Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT01519323 Malignant Melanoma Phase 1 Terminated(Study was terminate... More >>d due to low enrollment.) Less << - -
NCT01791309 Metastatic Colorectal Cancer Phase 1 Completed - United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01519323 - Terminated(Study was terminate... More >>d due to low enrollment.) Less << - -
NCT01959633 Melanoma Phase 1 Phase 2 Recruiting December 2017 Italy ... More >> Fondazione G.Pascale Recruiting Napoli, Italy, 80131 Principal Investigator: Paolo A Ascierto Less <<
NCT01667419 - Active, not recruiting - -
NCT02050321 - Terminated(Pharmaceutical comp... More >>any pulled support for the trial.) Less << - -
NCT01596140 Advanced Cancer ... More >> Solid Tumor Less << Phase 1 Active, not recruiting December 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01616199 Advanced BRAF-mutant Cancers Phase 1 Phase 2 Terminated(slow accrual) - United States, Florida ... More >> H. Lee Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, New York New York University New York, New York, United States, 10016 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 Less <<
NCT02050321 Malignant Melanoma Phase 2 Terminated(Pharmaceutical comp... More >>any pulled support for the trial.) Less << - United States, Arizona ... More >> University of Arizona Cancer Center Tucson, Arizona, United States, 85724 Less <<
NCT01307397 Malignant Melanoma PHASE3 COMPLETED 2016-02-24 University "Mother Theresa" Ho... More >>spital Center; Oncology Department, Tirana, 1000, Albania|Hospital Britanico; Oncologia, Buenos Aires, C1280AEB, Argentina|Fundación CIDEA, Buenos Aires, C1425DTG, Argentina|Inst. Alexander Fleming; Oncologia, Buenos Aires, C1426ANZ, Argentina|Melanoma Institute Australia, North Sydney, New South Wales, 2060, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, 2298, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Border Medical Oncology, Wodonga, New South Wales, 3690, Australia|Greenslopes Private Hospital; Gallipoli Research Centre, Greenslopes, Queensland, 4120, Australia|The Townsville Hospital; Townsville Cancer Centre, Townsville, Queensland, 4812, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital; Oncology, Adelaide, South Australia, 5000, Australia|Geelong Hospital; Geelong Cardiology Practice, Geelong, Victoria, 3220, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, 3000, Australia|Alfred Hospital, Melbourne, Victoria, 3004, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Landeskrankenhaus Feldkirch; Abteilung für Innere Medizin, Feldkirch, 6807, Austria|LKH Graz; Abteilung für allgemeine Dermatologie, Graz, 8036, Austria|LKH Innsbruck; Universit?tsklinik für Dermatologie, Innsbruck, 6020, Austria|Krankenhaus der Elisabethinen Linz; Abteilung für Dermatologie, Linz, 4020, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, 5020, Austria|LKH Salzburg; Universit?tsklinik für Dermatologie, Salzburg, 5020, Austria|Landesklinikum St. P?lten, St. P?lten, 3100, Austria|Medizinische Universit?t Wien; Univ.Klinik für Dermatologie, Wien, 1090, Austria|UZ Brussel, Brussel, 1090, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|Sint Augustinus Wilrijk, Wilrijk, 2610, Belgium|University Clinical Center of the Republic of Srpska, Banja Luka, 78000, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|Instituto Nacional de Cancer - INCa; Pesquisa Clinica, Rio de Janeiro, RJ, 20230-130, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, 90035-003, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, 01246-000, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, 01509-010, Brazil|Hospital Sao Jose, S?o Paulo, SP, CEP 01321-001, Brazil|District Oncology Dispensary; Department for Oncology and Dermatology, Plovdiv, 4000, Bulgaria|National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic, Sofia, 1756, Bulgaria|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, T6G 1Z2, Canada|Lion'S Gate Hospital, North Vancouver, British Columbia, V7L 2L7, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|St. Boniface General Hospital; Medicine, Winnipeg, Manitoba, R2H 2A6, Canada|QEII HSC; Oncology, Halifax, Nova Scotia, B3H 2Y9, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|London Regional Cancer Centre, London, Ontario, N6A 4L6, Canada|The Ottawa Hospital; Division of Infectious Diseases, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, M5G 2M9, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, H3T 1E2, Canada|Chuq - Hopital Hotel Dieu de Quebec; Oncology, Quebec City, Quebec, G1R 2J6, Canada|Centro Javeriano de Oncología, Bogota, Colombia|Fundacion Santa Fe de Bogotá, Bogota, Colombia|Clínica Imbanaco; Oncology, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Clinical Hospital Sisters of Mercy, Zagreb, 10000, Croatia|Masaryk?v onkologicky ústav; Klinika komplexní onkologické pé?e, Brno, 656 53, Czechia|University Hospital; Oncology and Radiotherapy, Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, 779 00, Czechia|Faculty Hospital; Dialysis Unit, Ostrava, 708 52, Czechia|1 Lekarska Fakulta Uni Karlovy; 3 Interni Klinika, Labor. Pro Endokrinologii A Metabolismus, Praha, 128 00, Czechia|Faculty Hospital Kralovske Vinohrady; Oncology, Praha, Czechia|Aarhus Universitetshospital; Kr?ftafdelingen, Aarhus C, 8000, Denmark|Herlev Hospital; Onkologisk afdeling, Herlev, 2730, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense, 5000, Denmark|Hospital Regional Vicente Corral Moscoso, Servicio de Oncología, Cuenca, Ecuador|Hospital Abel Gilbert Ponton; Oncology, Guayaquil, EC090104, Ecuador|Hospital Solca Portoviejo; Oncologia, Portoviejo, EC130104, Ecuador|East Tallinn Central Hospital; Clinic of Internal Medicine, Tallinn, 11312, Estonia|North Estonia Medical Centre Foundation; Oncology Center, Tallinn, 13419, Estonia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, 50406, Estonia|Helsinki University Central Hospital; Dept of Oncology, Helsinki, 00029, Finland|Tampere University Hospital; Dept of Oncology, Tampere, 33520, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, 20520, Finland|Uniklinik RWTH Aachen; Klinik für Dermatologie und Allergologie - Hautklinik, Aachen, 52074, Germany|Klinikum Augsburg Süd; Klinik für Dermatologie und Allergologie, Augsburg, 86179, Germany|CAMPUS BENJAMIN FRANKLIN CharitéCentrum 14 Med.Klinik f.H?matologie u.Onkologie, Berlin, 12200, Germany|St. Josef-Hospital Klinik f. Dermatologie u. Allergologie, Bochum, 44791, Germany|Elbekliniken Buxtehude; Klinik für Dermatologie, Buxtehude, 21614, Germany|DRK-Krankenhaus; Hautklinik, Chemnitz, 09117, Germany|Universit?tsklinikum "Carl Gustav Carus"; Medizinische Klinik und Poliklinik I, Dresden, 01307, Germany|Universit?tsklinikum Düsseldorf; Hautklinik, Düsseldorf, 40225, Germany|HELIOS Klinikum Erfurt, Klinik für Hautkrankheiten und Allergologie, Erfurt, 99089, Germany|Universit?tsklinikum Erlangen; Hautklinik, Erlangen, 91054, Germany|Universit?tsklinikum Essen, Essen, 45122, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik fuer Allgemein- und Viszeralchirurgie, Frankfurt, 60596, Germany|Uniklinikum Freiburg Dermatol, Freiburg, 79104, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, 07548, Germany|Universit?tsmedizin G?ttingen Georg-August-Universit?t Zentrum Dermatologie, G?ttingen, 37075, Germany|Universit?tsklinikum Hamburg-Eppendorf Zentrum f.Innere Medizin Klinik f.Dermatologie, Hamburg, 20246, Germany|Medizinische Hochschule; Hautklinik Linden, Hannover, 30449, Germany|Uni-Hautklinik, Heidelberg, 69115, Germany|Klinikum am Gesundbrunnen; Tumorzentrum, Heilbronn, 74078, Germany|Universit?tsklinikum Jena; Klinik für Hautkrankheiten, Jena, 07743, Germany|Klinikum Kassel; Hautklinik, Kassel, 34125, Germany|UNI-Klinikum Campus Kiel Klinik f.Dermatologie Tagesklinik f.Dermatologie, Kiel, 24105, Germany|Klinik der Uni zu K?ln; Klinik & Poliklinik fuer Dermatologie & Venerologie, K?ln, 50937, Germany|Universit?tsklinikum Leipzig Klinik f.Dermatologie Venerologie u.Allergologie, Leipzig, 04103, Germany|Klinikum d.Stadt Ludwigshafen Hautklinik, Ludwigshafen, 67063, Germany|Universit?tsklinikum Schleswig-Holstein; Campus Lübeck, Lübeck, 23538, Germany|Universit?tsklinikum Magdeburg; Hautklinik; Klinik für Dermatologie und Venerologie, Magdeburg, 39120, Germany|Johannes Gutenberg Unis-Klinik; Dept For Dermatology, Mainz, 55131, Germany|Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie, Mannheim, 68167, Germany|Universit?tsklinikum Marburg Klinik f. Dermatologie, Marburg, 35043, Germany|Johannes-Wesling-Klinikum Minden; Onkologische Ambulanz / Tagesklinik, Minden, 32429, Germany|Klinikum der LMU München; Klinik und Poliklinik für Dermatologie und Allergologie, München, 80337, Germany|Staedtisches Krankenhaus Muenchen-Schwabing, Haematologie & Onkolgie, München, 80804, Germany|Universit?tsklinikum Münster, Münster, 48149, Germany|Fachklinik Hornheide; Internistische Onkologie, Münster, 48157, Germany|Klinikum Nürnberg Nord; Hautklinik; Klinik für Dermatologie, Nürnberg, 90419, Germany|Klinikum Dorothea Ch.Erxleben; Klinik für Dermatologie und Allergologie, Quedlinburg, 06484, Germany|KLINIKUM VEST GmbH Knappschaftskrankenhaus Abt.Haut- Allergie- Venen- und Umwelterkrankungen, Recklinghausen, 45657, Germany|Universit?tsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, 93053, Germany|Universitaets-Hautklinik Tuebingen, Tübingen, 72076, Germany|Wilhelm Fresenius Klinik; Klinik f. Dermatologie u. Allergologie, Wiesbaden, 65191, Germany|HELIOS Klinikum Barmen Zentrum Dermatologie Allergologie und Umweltmedizin, Wuppertal, 42283, Germany|Universit?tsklinikum Würzburg; Klinik und Poliklinik für Dermatologie Venerologie u. Allergologie, Würzburg, 97080, Germany|Laiko General Hospital; 1St Pathological Clinic, Athens, 115 27, Greece|Hospital Hygeia; 1St Oncology Dept., Athens, 15123, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, 711 10, Greece|Metropolitan Hospital; Dept. of Oncology, Piraeus, 185 47, Greece|Semmelweis Egyetem; Bor-, Nemikortani es Boronkologiai Klinika, Budapest, 1085, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, 1122, Hungary|Debreceni Egyetem OEC; Borgyogyaszati Klinika, Debrecen, 4012, Hungary|Pecsi Tudomanyegyetem AOK; Borgyogyaszati Klinika, Pecs, 7632, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp., Szeged, 6720, Hungary|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, 110085, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, 400012, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, 422004, India|Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, 500034, India|Chhatrapati Shahuji Maharaj Medical University; Department of Oncology, Lucknow, 226003, India|Regional Cancer Centre; Dept of Oncology, Trivandrum, 695 011, India|Christian Med Clg & Hspt, Vellore, 632004, India|Cork Uni Hospital; Oncology Dept, Cork, Ireland|St Vincent'S Uni Hospital; Medical Oncology, Dublin, 4, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, 7, Ireland|Mater Private Hospital, Dublin, 7, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Galway Uni Hospital; Oncology Dept, Galway, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Waterford Regional Hospital; Department Of Medical Oncology, Waterford, Ireland|Soroka Medical Center; Oncology Dept, Beer Sheva, 8410101, Israel|Ranbam Health Care Campus; Oncology - Hafia, Hafia, 3109601, Israel|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, 91120-01, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, 5262100, Israel|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, 80131, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, 47014, Italy|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, 41100, Italy|AO Santa Maria Nuova; U.O. Day Hospital di Oncologi, Reggio Emilia, Emilia-Romagna, 42100, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, 33100, Italy|Istituto Dermopatico dell'Immacolata (IDI)-IRCCS; IV Divisione Oncologica e Dermatologia Oncologica, Roma, Lazio, 00167, Italy|IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, 00168, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, 16132, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, 24128, Italy|Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina, Brescia, Lombardia, 25123, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, 20132, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, 20133, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, 20141, Italy|Policlinico Le Molinette; Clinica Dermatologica, Torino, Piemonte, 10126, Italy|Istituto Tumori Giovanni Paolo II IRCSS; Ospedale Oncologico Bari, Bari, Puglia, 70126, Italy|Policlinico P. Giaccone; Istituto Di Oncologia, Clinica Medica 1, Palermo, Sicilia, 90127, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, 50139, Italy|Azienda Ospedaliera S. Chiara; Dip di Onc,Trapianti e delle Nuove Tecnologie in Medicina, Pisa, Toscana, 50126, Italy|A.O.U. Senese Policlinico Santa Maria Alle Scotte, Siena, Toscana, 53100, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, 05100, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, 35128, Italy|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Seoul St Mary's Hospital, Seoul, 06591, Korea, Republic of|Seoul National University Hosp; Dept Internal Med Hem Onc, Seoul, 110-744, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, 120-752, Korea, Republic of|Asan Medical Center., Seoul, 138-736, Korea, Republic of|Daugavpils Regional Hospital, Daugavpils, 5417, Latvia|Rigas Austrumu Kliniska Universitates slimnica, Latvijas Onkologijas centrs, Riga, LV 1079, Latvia|Klaipeda University Hospital, Klaipeda, 92288, Lithuania|Vilnius University Hospital Santariskiu Clinic, Hematology, Oncology and Tranfusion Medicine Center, Vilnius, 08661, Lithuania|University Clinic for Radiotherapy and Oncology Skopje; Department of skin malignancies, Skopje, 1000, Macedonia, The Former Yugoslav Republic of|Fundación Rodolfo Padilla Padilla, A.C.; Oncology, Leon, 37000, Mexico|Inst. Nacional de Cancerologia; Investigacion Clinica, Mexico City, 14000, Mexico|Hospital General de México; Unidad de Oncologia, Mexico DF, 06726, Mexico|Antoni Van Leeuwenhoek Ziekenhuis; Inwendige Geneeskunde, Amsterdam, 1066 CX, Netherlands|VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, 1081 HV, Netherlands|Tergooiziekenhuizen, Blaricum, 1261 AN, Netherlands|Amphia Ziekenhuis, Breda, 4818 CK, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, 9713 GZ, Netherlands|Academisch Ziekenhuis Leiden; Clinical Oncology, Leiden, 2333 ZA, Netherlands|Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde, Maastricht, 6229 HX, Netherlands|UMC St Radboud; Interne Oncologie; Medical Oncology Department, Nijmegen, 6500 HB, Netherlands|Erasmus MC, Rotterdam, 3000 CA, Netherlands|Universitair Medisch Centrum Utrecht; Inwendige Geneeskunde Afd., Utrecht, 3584 CX, Netherlands|Haukeland Universitetshospital; Onkologisk Avd., Bergen, 5021, Norway|The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, 0379, Norway|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, 04001, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, 34, Peru|Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii, Krakow, 31-531, Poland|ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii;Wojska Polskiego 37, Olsztyn, 10-228, Poland|NZOZ Med.-Polonia sp. z o.o., Poznań, 60-693, Poland|Centrum Onkologii- Instytut; im. M.Sk?odowskiej-Curie, Warszawa, 02-781, Poland|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, 1099-023, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, 4200-072, Portugal|Institut of Oncology Al. Trestioreanu Bucharest; Oncology, Bucuresti, 022328, Romania|Medisprof SRL, Cluj-Napoca, 400058, Romania|S.C. Life Search S.R.L; Medical Oncology Clinic, Timisoara, 300167, Romania|FSBI "Scientific Research Institute of Oncology named after N.N.Petrov" Ministry of Health of RF, St Petersburg, Leningrad, 197758, Russian Federation|Regional Clinical Oncology Dispensary, Krasnodar, 350040, Russian Federation|Russian Cancer Research Center, Moscow, 115478, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, 143423, Russian Federation|St. Petersburg Oncology & Gynecology; City Clinical Oncology Dispensary, Saint-Petersburg, 197022, Russian Federation|Stavropol Clinical Oncology Dispansary, Stavropol, ND, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, 450054, Russian Federation|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, 11000, Serbia|Clinical Center Bezanijska Kosa; Oncology, Belgrade, 11080, Serbia|Onkologicky ustav sv. Alzbety; Oddelenie ambulantnej chemoterapie, Bratislava, 812 50, Slovakia|Narodny Onkologicky Ustav; Oddelenie klinickej onkologie E, Bratislava, 833 10, Slovakia|POKO Poprad; Department of Oncology, Poprad, 058 01, Slovakia|Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia|Universitas Annex, University of the Free State; Clinical Oncology, Bloemfontein, 9300, South Africa|Cape Town Oncology Trials, Cape Town, 7570, South Africa|Cancercare, Cape Town, 7700, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, 2196, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, 0002, South Africa|Sandton Oncology Centre, Sandton, 2196, South Africa|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, 33011, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, 39008, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, 07014, Spain|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia, Las Palmas de Gran Canaria, Las Palmas, 35016, Spain|Hospital Universitario de Santa Lucía; Servicio de Oncología Médica, Cartagena (Murcia), Murcia, 30202, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, 31008, Spain|Hospital Xeral Cíes; Servicio de Oncologia, Vigo, Pontevedra, 36312, Spain|Hospital Universitario de Canarias (HUC), La Laguna (Tenerife), Tenerife, 38320, Spain|Hospital de Cruces; Servicio de Oncologia, Barakaldo, Vizcaya, 48903, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, 08035, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, 08036, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Barcelona, 08916, Spain|Hospital Reina Sofia, Cordoba, 14004, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Oncologia, Granada, 18014, Spain|Complejo Hospitalario Universitario A Coru?a (CHUAC, Materno Infantil), Oncología, La Coru?a, 15006, Spain|Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, 24071, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, 28034, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, 28041, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, 28046, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, 29010, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, 29010, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, 37007, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, 41009, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, 41014, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, 46009, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, 50009, Spain|Sahlgrenska Universitetssjukhuset; Onkology, Gothenburg, SE-41 343, Sweden|Sk?nes Onkologiska Klinik, Universitetssjukhuset, Lund, 22185, Sweden|Karolinska Universitetssjukhuset, Solna, Stockholm, 171 76, Sweden|Norrlands universitetssjukhus; Onkologkliniken, Ume?, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, 75185, Sweden|Universitaetsspital Basel; Onkologie, Basel, 4031, Switzerland|Inselspital Bern; Medizinische Onkologie, Bern, 3010, Switzerland|Kantonsspital Graubünden;Onkologie und H?matologie, Chur, 7000, Switzerland|CHUV; Departement d'Oncologie, Lausanne, 1011, Switzerland|Kantonsspital St. Gallen; Onkologie/H?matologie, St. Gallen, 9007, Switzerland|Universit?tsspital Zürich; Dermatologische Klinik, Zürich, 8091, Switzerland|Adana Baskent University Hospital; Medical Oncology, Adana, 01120, Turkey|Cukurova Uni Faculty of Medicine; Medical Oncology, Adana, 01330, Turkey|Ankara Uni , Ibn-I Sina Hospital; Oncology Dept, Ankara, 06230, Turkey|Gazi Uni Medical Faculty Hospital; Oncology Dept, Ankara, 06500, Turkey|Akdeniz University School of Medicine; General Surgery, Antalya, 07000, Turkey|Ege University Medical Faculty; Medical Oncology Department, Bornova, ?ZM?R, 35100, Turkey|Gaziantep University Medical Faculty, Medical Oncology Department, Gaziantep, 27310, Turkey|Kartal Training and Research Hospital;Medical Oncology Department, Istanbul, 34000, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, 34300, Turkey|American Hospital, Medical Oncology Department, Istanbul, 34365, Turkey|Dokuz Eylul Uni ; Medical Oncology, Izmir, 35340, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, S?hhiye, ANKARA, 06100, Turkey|Addenbrookes Nhs Trust; Oncology Clinical Trials Unit, Cambridge, CB2 0QQ, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Royal Surrey County Hospital; St. Lukes Cancer Centre, Guildford, GU2 7XX, United Kingdom|St James University Hospital, Leeds, LS9 7TF, United Kingdom|Royal Marsden Hospital, London, SW3 6JJ, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, M20 4QL, United Kingdom|Northern Centre for Cancer Care Freeman Hospital; Sir Bobby Robson Cancer Trials Research Centre, Newcastle upon Tyne, NE7 7DN, United Kingdom|Mount Vernon Hospital; Centre For Cancer Treatment, Northwood, HA6 2RN, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, NG5 1PB, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, OX3 7LJ, United Kingdom|Southampton General Hospital; Medical Oncology, Southampton, SO16 6YD, United Kingdom|Singleton Hospital; Oncology, Swansea, SA2 8QA, United Kingdom Less <<
NCT01709292 Thyroid Cancer Phase 2 Active, not recruiting November 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02230306 Active Melanoma Brain Metastas... More >>es Less << Phase 2 Terminated(closed due to slow ... More >>accrual) Less << - United States, Connecticut ... More >> Harriet Kluger New Haven, Connecticut, United States, 06510 United States, Iowa Mohammed Milhem, MD Iowa City, Iowa, United States, 52242 United States, New York Anna Pavlick, MD New York, New York, United States, 10016 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania Ravi Amaravadi, MD Philadelphia, Pennsylvania, United States, 19104 UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT01307397 Malignant Melanoma PHASE3 COMPLETED 2016-02-24 University "Mother Theresa" Ho... More >>spital Center; Oncology Department, Tirana, 1000, Albania|Hospital Britanico; Oncologia, Buenos Aires, C1280AEB, Argentina|Fundación CIDEA, Buenos Aires, C1425DTG, Argentina|Inst. Alexander Fleming; Oncologia, Buenos Aires, C1426ANZ, Argentina|Melanoma Institute Australia, North Sydney, New South Wales, 2060, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, 2298, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Border Medical Oncology, Wodonga, New South Wales, 3690, Australia|Greenslopes Private Hospital; Gallipoli Research Centre, Greenslopes, Queensland, 4120, Australia|The Townsville Hospital; Townsville Cancer Centre, Townsville, Queensland, 4812, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital; Oncology, Adelaide, South Australia, 5000, Australia|Geelong Hospital; Geelong Cardiology Practice, Geelong, Victoria, 3220, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, 3000, Australia|Alfred Hospital, Melbourne, Victoria, 3004, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Landeskrankenhaus Feldkirch; Abteilung für Innere Medizin, Feldkirch, 6807, Austria|LKH Graz; Abteilung für allgemeine Dermatologie, Graz, 8036, Austria|LKH Innsbruck; Universit?tsklinik für Dermatologie, Innsbruck, 6020, Austria|Krankenhaus der Elisabethinen Linz; Abteilung für Dermatologie, Linz, 4020, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, 5020, Austria|LKH Salzburg; Universit?tsklinik für Dermatologie, Salzburg, 5020, Austria|Landesklinikum St. P?lten, St. P?lten, 3100, Austria|Medizinische Universit?t Wien; Univ.Klinik für Dermatologie, Wien, 1090, Austria|UZ Brussel, Brussel, 1090, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|Sint Augustinus Wilrijk, Wilrijk, 2610, Belgium|University Clinical Center of the Republic of Srpska, Banja Luka, 78000, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|Instituto Nacional de Cancer - INCa; Pesquisa Clinica, Rio de Janeiro, RJ, 20230-130, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, 90035-003, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, 01246-000, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, 01509-010, Brazil|Hospital Sao Jose, S?o Paulo, SP, CEP 01321-001, Brazil|District Oncology Dispensary; Department for Oncology and Dermatology, Plovdiv, 4000, Bulgaria|National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic, Sofia, 1756, Bulgaria|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, T6G 1Z2, Canada|Lion'S Gate Hospital, North Vancouver, British Columbia, V7L 2L7, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|St. Boniface General Hospital; Medicine, Winnipeg, Manitoba, R2H 2A6, Canada|QEII HSC; Oncology, Halifax, Nova Scotia, B3H 2Y9, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|London Regional Cancer Centre, London, Ontario, N6A 4L6, Canada|The Ottawa Hospital; Division of Infectious Diseases, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, M5G 2M9, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, H3T 1E2, Canada|Chuq - Hopital Hotel Dieu de Quebec; Oncology, Quebec City, Quebec, G1R 2J6, Canada|Centro Javeriano de Oncología, Bogota, Colombia|Fundacion Santa Fe de Bogotá, Bogota, Colombia|Clínica Imbanaco; Oncology, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Clinical Hospital Sisters of Mercy, Zagreb, 10000, Croatia|Masaryk?v onkologicky ústav; Klinika komplexní onkologické pé?e, Brno, 656 53, Czechia|University Hospital; Oncology and Radiotherapy, Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, 779 00, Czechia|Faculty Hospital; Dialysis Unit, Ostrava, 708 52, Czechia|1 Lekarska Fakulta Uni Karlovy; 3 Interni Klinika, Labor. Pro Endokrinologii A Metabolismus, Praha, 128 00, Czechia|Faculty Hospital Kralovske Vinohrady; Oncology, Praha, Czechia|Aarhus Universitetshospital; Kr?ftafdelingen, Aarhus C, 8000, Denmark|Herlev Hospital; Onkologisk afdeling, Herlev, 2730, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense, 5000, Denmark|Hospital Regional Vicente Corral Moscoso, Servicio de Oncología, Cuenca, Ecuador|Hospital Abel Gilbert Ponton; Oncology, Guayaquil, EC090104, Ecuador|Hospital Solca Portoviejo; Oncologia, Portoviejo, EC130104, Ecuador|East Tallinn Central Hospital; Clinic of Internal Medicine, Tallinn, 11312, Estonia|North Estonia Medical Centre Foundation; Oncology Center, Tallinn, 13419, Estonia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, 50406, Estonia|Helsinki University Central Hospital; Dept of Oncology, Helsinki, 00029, Finland|Tampere University Hospital; Dept of Oncology, Tampere, 33520, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, 20520, Finland|Uniklinik RWTH Aachen; Klinik für Dermatologie und Allergologie - Hautklinik, Aachen, 52074, Germany|Klinikum Augsburg Süd; Klinik für Dermatologie und Allergologie, Augsburg, 86179, Germany|CAMPUS BENJAMIN FRANKLIN CharitéCentrum 14 Med.Klinik f.H?matologie u.Onkologie, Berlin, 12200, Germany|St. Josef-Hospital Klinik f. Dermatologie u. Allergologie, Bochum, 44791, Germany|Elbekliniken Buxtehude; Klinik für Dermatologie, Buxtehude, 21614, Germany|DRK-Krankenhaus; Hautklinik, Chemnitz, 09117, Germany|Universit?tsklinikum "Carl Gustav Carus"; Medizinische Klinik und Poliklinik I, Dresden, 01307, Germany|Universit?tsklinikum Düsseldorf; Hautklinik, Düsseldorf, 40225, Germany|HELIOS Klinikum Erfurt, Klinik für Hautkrankheiten und Allergologie, Erfurt, 99089, Germany|Universit?tsklinikum Erlangen; Hautklinik, Erlangen, 91054, Germany|Universit?tsklinikum Essen, Essen, 45122, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik fuer Allgemein- und Viszeralchirurgie, Frankfurt, 60596, Germany|Uniklinikum Freiburg Dermatol, Freiburg, 79104, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, 07548, Germany|Universit?tsmedizin G?ttingen Georg-August-Universit?t Zentrum Dermatologie, G?ttingen, 37075, Germany|Universit?tsklinikum Hamburg-Eppendorf Zentrum f.Innere Medizin Klinik f.Dermatologie, Hamburg, 20246, Germany|Medizinische Hochschule; Hautklinik Linden, Hannover, 30449, Germany|Uni-Hautklinik, Heidelberg, 69115, Germany|Klinikum am Gesundbrunnen; Tumorzentrum, Heilbronn, 74078, Germany|Universit?tsklinikum Jena; Klinik für Hautkrankheiten, Jena, 07743, Germany|Klinikum Kassel; Hautklinik, Kassel, 34125, Germany|UNI-Klinikum Campus Kiel Klinik f.Dermatologie Tagesklinik f.Dermatologie, Kiel, 24105, Germany|Klinik der Uni zu K?ln; Klinik & Poliklinik fuer Dermatologie & Venerologie, K?ln, 50937, Germany|Universit?tsklinikum Leipzig Klinik f.Dermatologie Venerologie u.Allergologie, Leipzig, 04103, Germany|Klinikum d.Stadt Ludwigshafen Hautklinik, Ludwigshafen, 67063, Germany|Universit?tsklinikum Schleswig-Holstein; Campus Lübeck, Lübeck, 23538, Germany|Universit?tsklinikum Magdeburg; Hautklinik; Klinik für Dermatologie und Venerologie, Magdeburg, 39120, Germany|Johannes Gutenberg Unis-Klinik; Dept For Dermatology, Mainz, 55131, Germany|Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie, Mannheim, 68167, Germany|Universit?tsklinikum Marburg Klinik f. Dermatologie, Marburg, 35043, Germany|Johannes-Wesling-Klinikum Minden; Onkologische Ambulanz / Tagesklinik, Minden, 32429, Germany|Klinikum der LMU München; Klinik und Poliklinik für Dermatologie und Allergologie, München, 80337, Germany|Staedtisches Krankenhaus Muenchen-Schwabing, Haematologie & Onkolgie, München, 80804, Germany|Universit?tsklinikum Münster, Münster, 48149, Germany|Fachklinik Hornheide; Internistische Onkologie, Münster, 48157, Germany|Klinikum Nürnberg Nord; Hautklinik; Klinik für Dermatologie, Nürnberg, 90419, Germany|Klinikum Dorothea Ch.Erxleben; Klinik für Dermatologie und Allergologie, Quedlinburg, 06484, Germany|KLINIKUM VEST GmbH Knappschaftskrankenhaus Abt.Haut- Allergie- Venen- und Umwelterkrankungen, Recklinghausen, 45657, Germany|Universit?tsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, 93053, Germany|Universitaets-Hautklinik Tuebingen, Tübingen, 72076, Germany|Wilhelm Fresenius Klinik; Klinik f. Dermatologie u. Allergologie, Wiesbaden, 65191, Germany|HELIOS Klinikum Barmen Zentrum Dermatologie Allergologie und Umweltmedizin, Wuppertal, 42283, Germany|Universit?tsklinikum Würzburg; Klinik und Poliklinik für Dermatologie Venerologie u. Allergologie, Würzburg, 97080, Germany|Laiko General Hospital; 1St Pathological Clinic, Athens, 115 27, Greece|Hospital Hygeia; 1St Oncology Dept., Athens, 15123, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, 711 10, Greece|Metropolitan Hospital; Dept. of Oncology, Piraeus, 185 47, Greece|Semmelweis Egyetem; Bor-, Nemikortani es Boronkologiai Klinika, Budapest, 1085, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, 1122, Hungary|Debreceni Egyetem OEC; Borgyogyaszati Klinika, Debrecen, 4012, Hungary|Pecsi Tudomanyegyetem AOK; Borgyogyaszati Klinika, Pecs, 7632, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp., Szeged, 6720, Hungary|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, 110085, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, 400012, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, 422004, India|Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, 500034, India|Chhatrapati Shahuji Maharaj Medical University; Department of Oncology, Lucknow, 226003, India|Regional Cancer Centre; Dept of Oncology, Trivandrum, 695 011, India|Christian Med Clg & Hspt, Vellore, 632004, India|Cork Uni Hospital; Oncology Dept, Cork, Ireland|St Vincent'S Uni Hospital; Medical Oncology, Dublin, 4, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, 7, Ireland|Mater Private Hospital, Dublin, 7, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Galway Uni Hospital; Oncology Dept, Galway, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Waterford Regional Hospital; Department Of Medical Oncology, Waterford, Ireland|Soroka Medical Center; Oncology Dept, Beer Sheva, 8410101, Israel|Ranbam Health Care Campus; Oncology - Hafia, Hafia, 3109601, Israel|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, 91120-01, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, 5262100, Israel|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, 80131, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, 47014, Italy|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, 41100, Italy|AO Santa Maria Nuova; U.O. Day Hospital di Oncologi, Reggio Emilia, Emilia-Romagna, 42100, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, 33100, Italy|Istituto Dermopatico dell'Immacolata (IDI)-IRCCS; IV Divisione Oncologica e Dermatologia Oncologica, Roma, Lazio, 00167, Italy|IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, 00168, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, 16132, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, 24128, Italy|Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina, Brescia, Lombardia, 25123, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, 20132, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, 20133, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, 20141, Italy|Policlinico Le Molinette; Clinica Dermatologica, Torino, Piemonte, 10126, Italy|Istituto Tumori Giovanni Paolo II IRCSS; Ospedale Oncologico Bari, Bari, Puglia, 70126, Italy|Policlinico P. Giaccone; Istituto Di Oncologia, Clinica Medica 1, Palermo, Sicilia, 90127, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, 50139, Italy|Azienda Ospedaliera S. Chiara; Dip di Onc,Trapianti e delle Nuove Tecnologie in Medicina, Pisa, Toscana, 50126, Italy|A.O.U. Senese Policlinico Santa Maria Alle Scotte, Siena, Toscana, 53100, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, 05100, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, 35128, Italy|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Seoul St Mary's Hospital, Seoul, 06591, Korea, Republic of|Seoul National University Hosp; Dept Internal Med Hem Onc, Seoul, 110-744, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, 120-752, Korea, Republic of|Asan Medical Center., Seoul, 138-736, Korea, Republic of|Daugavpils Regional Hospital, Daugavpils, 5417, Latvia|Rigas Austrumu Kliniska Universitates slimnica, Latvijas Onkologijas centrs, Riga, LV 1079, Latvia|Klaipeda University Hospital, Klaipeda, 92288, Lithuania|Vilnius University Hospital Santariskiu Clinic, Hematology, Oncology and Tranfusion Medicine Center, Vilnius, 08661, Lithuania|University Clinic for Radiotherapy and Oncology Skopje; Department of skin malignancies, Skopje, 1000, Macedonia, The Former Yugoslav Republic of|Fundación Rodolfo Padilla Padilla, A.C.; Oncology, Leon, 37000, Mexico|Inst. Nacional de Cancerologia; Investigacion Clinica, Mexico City, 14000, Mexico|Hospital General de México; Unidad de Oncologia, Mexico DF, 06726, Mexico|Antoni Van Leeuwenhoek Ziekenhuis; Inwendige Geneeskunde, Amsterdam, 1066 CX, Netherlands|VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, 1081 HV, Netherlands|Tergooiziekenhuizen, Blaricum, 1261 AN, Netherlands|Amphia Ziekenhuis, Breda, 4818 CK, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, 9713 GZ, Netherlands|Academisch Ziekenhuis Leiden; Clinical Oncology, Leiden, 2333 ZA, Netherlands|Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde, Maastricht, 6229 HX, Netherlands|UMC St Radboud; Interne Oncologie; Medical Oncology Department, Nijmegen, 6500 HB, Netherlands|Erasmus MC, Rotterdam, 3000 CA, Netherlands|Universitair Medisch Centrum Utrecht; Inwendige Geneeskunde Afd., Utrecht, 3584 CX, Netherlands|Haukeland Universitetshospital; Onkologisk Avd., Bergen, 5021, Norway|The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, 0379, Norway|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, 04001, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, 34, Peru|Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii, Krakow, 31-531, Poland|ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii;Wojska Polskiego 37, Olsztyn, 10-228, Poland|NZOZ Med.-Polonia sp. z o.o., Poznań, 60-693, Poland|Centrum Onkologii- Instytut; im. M.Sk?odowskiej-Curie, Warszawa, 02-781, Poland|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, 1099-023, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, 4200-072, Portugal|Institut of Oncology Al. Trestioreanu Bucharest; Oncology, Bucuresti, 022328, Romania|Medisprof SRL, Cluj-Napoca, 400058, Romania|S.C. Life Search S.R.L; Medical Oncology Clinic, Timisoara, 300167, Romania|FSBI "Scientific Research Institute of Oncology named after N.N.Petrov" Ministry of Health of RF, St Petersburg, Leningrad, 197758, Russian Federation|Regional Clinical Oncology Dispensary, Krasnodar, 350040, Russian Federation|Russian Cancer Research Center, Moscow, 115478, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, 143423, Russian Federation|St. Petersburg Oncology & Gynecology; City Clinical Oncology Dispensary, Saint-Petersburg, 197022, Russian Federation|Stavropol Clinical Oncology Dispansary, Stavropol, ND, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, 450054, Russian Federation|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, 11000, Serbia|Clinical Center Bezanijska Kosa; Oncology, Belgrade, 11080, Serbia|Onkologicky ustav sv. Alzbety; Oddelenie ambulantnej chemoterapie, Bratislava, 812 50, Slovakia|Narodny Onkologicky Ustav; Oddelenie klinickej onkologie E, Bratislava, 833 10, Slovakia|POKO Poprad; Department of Oncology, Poprad, 058 01, Slovakia|Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia|Universitas Annex, University of the Free State; Clinical Oncology, Bloemfontein, 9300, South Africa|Cape Town Oncology Trials, Cape Town, 7570, South Africa|Cancercare, Cape Town, 7700, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, 2196, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, 0002, South Africa|Sandton Oncology Centre, Sandton, 2196, South Africa|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, 33011, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, 39008, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, 07014, Spain|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia, Las Palmas de Gran Canaria, Las Palmas, 35016, Spain|Hospital Universitario de Santa Lucía; Servicio de Oncología Médica, Cartagena (Murcia), Murcia, 30202, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, 31008, Spain|Hospital Xeral Cíes; Servicio de Oncologia, Vigo, Pontevedra, 36312, Spain|Hospital Universitario de Canarias (HUC), La Laguna (Tenerife), Tenerife, 38320, Spain|Hospital de Cruces; Servicio de Oncologia, Barakaldo, Vizcaya, 48903, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, 08035, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, 08036, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Barcelona, 08916, Spain|Hospital Reina Sofia, Cordoba, 14004, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Oncologia, Granada, 18014, Spain|Complejo Hospitalario Universitario A Coru?a (CHUAC, Materno Infantil), Oncología, La Coru?a, 15006, Spain|Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, 24071, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, 28034, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, 28041, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, 28046, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, 29010, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, 29010, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, 37007, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, 41009, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, 41014, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, 46009, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, 50009, Spain|Sahlgrenska Universitetssjukhuset; Onkology, Gothenburg, SE-41 343, Sweden|Sk?nes Onkologiska Klinik, Universitetssjukhuset, Lund, 22185, Sweden|Karolinska Universitetssjukhuset, Solna, Stockholm, 171 76, Sweden|Norrlands universitetssjukhus; Onkologkliniken, Ume?, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, 75185, Sweden|Universitaetsspital Basel; Onkologie, Basel, 4031, Switzerland|Inselspital Bern; Medizinische Onkologie, Bern, 3010, Switzerland|Kantonsspital Graubünden;Onkologie und H?matologie, Chur, 7000, Switzerland|CHUV; Departement d'Oncologie, Lausanne, 1011, Switzerland|Kantonsspital St. Gallen; Onkologie/H?matologie, St. Gallen, 9007, Switzerland|Universit?tsspital Zürich; Dermatologische Klinik, Zürich, 8091, Switzerland|Adana Baskent University Hospital; Medical Oncology, Adana, 01120, Turkey|Cukurova Uni Faculty of Medicine; Medical Oncology, Adana, 01330, Turkey|Ankara Uni , Ibn-I Sina Hospital; Oncology Dept, Ankara, 06230, Turkey|Gazi Uni Medical Faculty Hospital; Oncology Dept, Ankara, 06500, Turkey|Akdeniz University School of Medicine; General Surgery, Antalya, 07000, Turkey|Ege University Medical Faculty; Medical Oncology Department, Bornova, ?ZM?R, 35100, Turkey|Gaziantep University Medical Faculty, Medical Oncology Department, Gaziantep, 27310, Turkey|Kartal Training and Research Hospital;Medical Oncology Department, Istanbul, 34000, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, 34300, Turkey|American Hospital, Medical Oncology Department, Istanbul, 34365, Turkey|Dokuz Eylul Uni ; Medical Oncology, Izmir, 35340, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, S?hhiye, ANKARA, 06100, Turkey|Addenbrookes Nhs Trust; Oncology Clinical Trials Unit, Cambridge, CB2 0QQ, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Royal Surrey County Hospital; St. Lukes Cancer Centre, Guildford, GU2 7XX, United Kingdom|St James University Hospital, Leeds, LS9 7TF, United Kingdom|Royal Marsden Hospital, London, SW3 6JJ, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, M20 4QL, United Kingdom|Northern Centre for Cancer Care Freeman Hospital; Sir Bobby Robson Cancer Trials Research Centre, Newcastle upon Tyne, NE7 7DN, United Kingdom|Mount Vernon Hospital; Centre For Cancer Treatment, Northwood, HA6 2RN, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, NG5 1PB, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, OX3 7LJ, United Kingdom|Southampton General Hospital; Medical Oncology, Southampton, SO16 6YD, United Kingdom|Singleton Hospital; Oncology, Swansea, SA2 8QA, United Kingdom Less <<
NCT01586195 Malignant Melanoma PHASE2 TERMINATED 2015-04-30 Arizona Cancer Center, Tucson,... More >> Arizona, 85724, United States|UCSD Moores Cancer Center, La Jolla, California, 92093, United States|UCLA School of Medicine; Hematology/Oncology, Los Angeles, California, 90095, United States|The Angeles Clinic and Research Institute, Santa Monica Office, Santa Monica, California, 90025, United States|University of Colorado; Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Emory University; Winship Cancer Institute, Atlanta, Georgia, 30308, United States|Oncology Specialists, S.C., Park Ridge, Illinois, 60068, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Atlantic Health System, Morristown, New Jersey, 07960, United States|Columbia University Medical Center, New York, New York, 10032, United States|Mid Ohio Onc Hematology Inc, Columbus, Ohio, 43219, United States|UPCI Cancer Institute; Cancer Pavillion, Pittsburgh, Pennsylvania, 15232, United States|Vanderbilt Univ Medical Ctr, Nashville, Tennessee, 37232, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, 75246, United States Less <<
NCT01586195 Malignant Melanoma PHASE2 TERMINATED 2015-04-30 Arizona Cancer Center, Tucson,... More >> Arizona, 85724, United States|UCSD Moores Cancer Center, La Jolla, California, 92093, United States|UCLA School of Medicine; Hematology/Oncology, Los Angeles, California, 90095, United States|The Angeles Clinic and Research Institute, Santa Monica Office, Santa Monica, California, 90025, United States|University of Colorado; Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Emory University; Winship Cancer Institute, Atlanta, Georgia, 30308, United States|Oncology Specialists, S.C., Park Ridge, Illinois, 60068, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Atlantic Health System, Morristown, New Jersey, 07960, United States|Columbia University Medical Center, New York, New York, 10032, United States|Mid Ohio Onc Hematology Inc, Columbus, Ohio, 43219, United States|UPCI Cancer Institute; Cancer Pavillion, Pittsburgh, Pennsylvania, 15232, United States|Vanderbilt Univ Medical Ctr, Nashville, Tennessee, 37232, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, 75246, United States Less <<
NCT01942993 Melanoma PHASE2 TERMINATED 2025-11-15 Icahn School of Medicine at Mo... More >>unt Sinai, New York, New York, 11103, United States Less <<
NCT02230306 - Terminated(closed due to slow ... More >>accrual) Less << - -
NCT01767623 Neoplasms PHASE1 COMPLETED 2017-04-20 California Cancer Associates f... More >>or Research & Excellence, Inc., Encinitas, California, 92008, United States|Peninsula and South Eastern Haematology and Oncology Grou, Frankston, Victoria, 3199, Australia|District General Hospital of Athens Laiko; 1st Internal Medicine Clinic, Athens, 11527, Greece|Rambam Health Care Campus, Haifa, 31096, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 64239, Israel|SBIH " Clinical Oncological Dispensary # 1"; Chemotherapy department #1 and #2, Krasnodar, 350040, Russian Federation|Ege University Medicine Develoment and Pharmacokinetics Research Center; Pulmonary Diseases, Izmir, 35040, Turkey|Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom Less <<
NCT01910181 Malignant Melanoma PHASE1 COMPLETED 2018-04-20 Beijing Cancer Hospital, Beiji... More >>ng, 100142, China|Sun Yet-sen University Cancer Center, Guangzhou, 510060, China Less <<
NCT01910181 Malignant Melanoma PHASE1 COMPLETED 2018-04-20 Beijing Cancer Hospital, Beiji... More >>ng, 100142, China|Sun Yet-sen University Cancer Center, Guangzhou, 510060, China Less <<
NCT01813214 Melanoma Phase 2 Terminated(Recruitment difficu... More >>lties.) Less << - United States, District of Col... More >>umbia Georgetown Lombardi Comprehsnive Cancer Center Washington, District of Columbia, United States, 20007 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 United States, Texas University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Virginia University of Virginia Health System Charlottesville, Virginia, United States, 22903 Less <<
NCT01765543 Malignant Melanoma, Neoplasms Phase 1 Completed - United States, Arkansas ... More >> Rogers, Arkansas, United States, 72758 United States, California Pleasant Hill, California, United States, 94523 United States, Ohio Middletown, Ohio, United States, 45042 United States, Texas Dallas, Texas, United States, 75246 Brazil Porto Alegre, RS, Brazil, 90020-090 Porto Alegre, RS, Brazil, 90035-003 Porto Alegre, RS, Brazil, 90840-440 Croatia Varazdin, Croatia, 42000 Zagreb, Croatia, 10000 Egypt Alexandria, Egypt, 21131 Cairo, Egypt, 11796 Dakahlia, Egypt, 324 Tanta, Egypt South Africa Cape Town, South Africa, 7570 Port Elizabeth, South Africa, 6045 Less <<
NCT01813214 - Terminated(Recruitment difficu... More >>lties.) Less << - -
NCT01781026 Melanoma PHASE2 COMPLETED 2025-06-14 Smilow Cancer Hospital at Yale... More >> New Haven, New Haven, Connecticut, 06510, United States Less <<
NCT01983124 Malignant Melanoma Stage IV Phase 2 Completed - Italy ... More >> Paola Queirolo Genova, Italy, 16132 Istituto Nazionale per lo Studio e la Cura dei Tumori "G.Pascale" Napoli, Italy, 80131 Less <<
NCT02427893 Melanoma Phase 3 Withdrawn(no patients were enr... More >>olled) Less << - United States, Maryland ... More >> The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 Less <<
NCT01781026 Melanoma PHASE2 COMPLETED 2025-06-14 Smilow Cancer Hospital at Yale... More >> New Haven, New Haven, Connecticut, 06510, United States Less <<
NCT01739764 Neoplasms PHASE4 COMPLETED 2020-02-17 Highlands Oncology Group, Roge... More >>rs, Arkansas, 72758, United States|UCLA Department of Medicine, Los Angeles, California, 90024, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, 90502, United States|University of Chicago Medical Center; Medicine, Section of Pulmonary, Chicago, Illinois, 60637, United States|Siouxland Regional Cancer Center d/b/a June E. Nylen Cancer Center, Sioux City, Iowa, 51108, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States|New York University Medical Center PRIME, New York, New York, 10016, United States|Evelyn H. Lauder Center, New York, New York, 10065, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, 19104, United States|Mary Crowley Medical Research Center; Oncology, Dallas, Texas, 75246, United States|M D Anderson Physician Network, Webster, Texas, 77598, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, 98195, United States|N.N. Alexandrov National Cancer Centre of Belarus, Minsk District, 223040, Belarus|Institut Jules Bordet, Brussels, 1000, Belgium|University Clinical Center of the Republic of Srpska, Banja Luka, 78000, Bosnia and Herzegovina|University Clinic Centre Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, H3T 1E2, Canada|Clinical Hospital Center Sestre Milosrdnice, Zagreb, 10000, Croatia|Clinical Hospital Centre Zagreb, Zagreb, 10000, Croatia|Bank of Cyprus Oncology Center, Nicosia, 2006, Cyprus|Medical Research Institute, Alexandria, 21131, Egypt|National Cancer Institute, Cairo, 11796, Egypt|Mansoura University Hospital, Dakahlia, 324, Egypt|Gharbia Cancer Society, Tanta, Egypt|Centre Léon Bérard, Lyon, 69373, France|Institut Gustave Roussy, Villejuif, 94805, France|Universit?tsklinikum Heidelberg, Heidelberg, 69120, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Apotheke, Mainz, 55131, Germany|Universit?tsklinikum Wurzburg, Würzburg, 97080, Germany|University General Hospital of Heraklion, Crete, 711 10, Greece|Semmelweis Egyetem, Budapest, 1083, Hungary|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, H-1077, Hungary|Debreceni Egyetem Klinikai K?zpont; B?rgyógyászati Klinika, Debrecen, 4012, Hungary|Pecsi Tudomanyegyetem, Pecs, 7624, Hungary|Rambam Health Care Campus, Haifa, 3109600, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel|Chaim Sheba Medical Center; Allergy and Clinical Immunology Unit, Ramat Gan, 5266202, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, 56100, Italy|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|Samsung Medical Center, Seoul, (0)6351, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Maastricht University Medical Center, Maastricht, 6229 HX, Netherlands|Auckland City Hospital, Auckland, 1023, New Zealand|Christchurch Clinical Studies Trust, Christchurch, 8011, New Zealand|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, 1099-023, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, 4200-072, Portugal|Medisprof SRL, Cluj-Napoca, 400058, Romania|FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"; Chemotherapy Departement, Moskva, Moskovskaja Oblast, 115478, Russian Federation|Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic, Kazan, 420029, Russian Federation|SBIH " Clinical Oncological Dispensary # 1"; Chemotherapy department #1 and #2, Krasnodar, 350040, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, 143423, Russian Federation|St. Petersburg SHI "City Clinical Oncology Dispensary", Saint-Petersburg, 197022, Russian Federation|SBIH Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, 450054, Russian Federation|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, 11000, Serbia|Clinical Center Bezanijska Kosa, Belgrade, 11070, Serbia|Cape Town Oncology Trials, Cape Town, 7570, South Africa|Wits Donald Gordon Clinical Trial Centre; Medical Oncology, Parktown, Johannesburg, 2193, South Africa|Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth, 6045, South Africa|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, 39008, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, 07010, Spain|Complejo Hospitalario Universitario A Coru?a, A Coru?a, LA Coru?a, 15006, Spain|Hospital Regional Universitario de Malaga; Oncologia, Málaga, Malaga, 29010, Spain|Hospital General Universitario Santa Lucia, Cartagena (Murcia), Murcia, 30202, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, 08036, Spain|Hospital Universitario La Paz, Madrid, 280146, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, 28050, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, 46009, Spain|Hospital General Universitario de Valencia, Valencia, 46014, Spain|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Churchill Hospital, Oxford, OX3 7LJ, United Kingdom|Royal Marsden Hospital, Surrey, SM2 5PT, United Kingdom Less <<
NCT02036086 Melanoma Phase 2 Recruiting October 2022 Canada, Ontario ... More >> The Ottawa Hospital - General Campus Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: Carolyn Nessim, MD, MSc    613-737-8899 ext 71085    cnessim@toh.on.ca    Principal Investigator: Carolyn Nessim, MD, MSc          Sunnybrook Health Sciences Centre Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Teresa Petrella, MD, BSc, MSc    416 480 5248    teresa.petrella@sunnybrook.ca    Principal Investigator: Teresa Petrella, MD, BSc, MSc          Canada, Quebec Royal Victoria Hospital Recruiting Montreal, Quebec, Canada, H3A 1A1 Contact: Catalin Mihalcioiu, MD    514 934 1934 ext 35800    catalin.mihalcioiu@muhc.mcgill.ca    Principal Investigator: Catalin Mihalcioiu, MD Less <<
NCT01765543 - Completed - -
NCT02537600 Malignant Melanoma Phase 2 Recruiting June 2020 France ... More >> CHU de Bordeaux Not yet recruiting Bordeaux, France, 33000 Principal Investigator: Caroline DUTRIAUX          CHU Ambroise Paré Recruiting Boulogne, France, 92104 Principal Investigator: Philippe SAIAG, Professor          CHU Brest - Hôpital Morvan Recruiting Brest, France Principal Investigator: Delphine LEGOUPIL          CHU Caen - Hôpital Clémenceau Recruiting Caen, France, 14033 Principal Investigator: Michel DE PONTVILLE, MD          Hôpital Henri Mondor Recruiting Creteil, France, 94010 Principal Investigator: Ouidad ZEHOU          CHU de Dijon Not yet recruiting Dijon, France Principal Investigator: Sophie DALAC-RAT          CHU Albert Michallon Recruiting Grenoble, France, 38014 Principal Investigator: Marie-Thérèse LECCIA          Centre Hospitalier du Mans Recruiting Le Mans, France, 72037 Principal Investigator: Nathalie BENETON          CHRU Lille Recruiting Lille, France, 59037 Principal Investigator: Laurent MORTIER, Professor          Centre Hospitalier Lyon Sud Not yet recruiting Lyon, France, 69495 Principal Investigator: Stéphane DALLE          Centre Hospitalier Annecy Genevois Not yet recruiting Metz-Tessy, France, 74370 Principal Investigator: Julie DE QUATREBARBES          CHU de Nantes Not yet recruiting Nantes, France, 44093 Principal Investigator: Brigitte DRENO          Groupe Hospitalier l'Archet Recruiting Nice, France, 06202 Principal Investigator: Jean-Philippe LACOUR, Professor          CHR Orléans Not yet recruiting Orléans, France, 45032 Principal Investigator: Guido BENS, MD          Hôîtal St louis Recruiting Paris, France, 75010 Principal Investigator: Céleste LEBBE, Professor          Hôpital Cochin Recruiting Paris, France, 75014 Principal Investigator: Nora KRAMKIMEL          Hôpital Bichat Not yet recruiting Paris, France, 75018 Principal Investigator: Eve MAUBEC, MD          Centre Eugène Marquis Recruiting Rennes, France, 35042 Principal Investigator: Thierry Lesimple, MD          Hôpital Charles Nicolle - CHU Rouen Not yet recruiting Rouen, France, 76031 Principal Investigator: Anne-Bénédicte DUVAL-MODESTE          Institut Claude Regaud Not yet recruiting Toulouse, France Principal Investigator: Nicolas MEYER          CHU Tours Recruiting Tours, France, 37044 Principal Investigator: Laurent MACHET, Professor          Institut Gustave Roussy Not yet recruiting Villejuif, France, 94805 Principal Investigator: Caroline ROBERT Less <<
NCT01711632 Hairy Cell Leukemia PHASE2 COMPLETED 2024-08-16 Scripps Clinic, La Jolla, Cali... More >>fornia, 92037, United States|Northwestern University, Evanston, Illinois, 60208, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Ohio State University, Columbus, Ohio, 43210, United States Less <<
NCT02456701 Thyroid Cancer Phase 1 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT03005639 Stage IIIB-C Melanoma Phase 2 Withdrawn(Sponsor has decided ... More >>to close study.) Less << - United States, Virginia ... More >> Inova Schar Cancer Institute Fairfax, Virginia, United States, 22031 Less <<
NCT01748149 Pediatric Recurrent/Refractory... More >> BRAFV600E-mutant Gliomas Less << EARLY_PHASE1 ACTIVE_NOT_RECRUITING 2025-12-31 Children's Hospital Los Angele... More >>s, Los Angeles, California, 90027, United States|Mattel Children's Hospital UCLA, Los Angeles, California, 90095, United States|Children's Hospital and Research Center at Oakland, Oakland, California, 94609-1809, United States|Rady Children's Hospital - San Diego, San Diego, California, 92123, United States|UCSF Medical Center-Mount Zion, San Francisco, California, 94115, United States|UCSF Medical Center-Parnassus, San Francisco, California, 94143, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, 32610, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, 60611, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Minnesota/Masonic Children's Hospital, Minneapolis, Minnesota, 55454, United States|Saint Louis Children's Hospital, Saint Louis, Missouri, 63110, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States|Texas Children's Hospital, Houston, Texas, 77030, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada Less <<
NCT02441465 Malignant Melanoma, Cancer Phase 1 Completed - Hungary ... More >> Magyar Honvedseg Egeszsegugyi Kozpont Budapest, Hungary, H-1134 Less <<
NCT02304809 Solid Tumors|Hematologic Cance... More >>rs|Metastatic Cancers Less << PHASE2 ACTIVE_NOT_RECRUITING 2027-10-13 Tredaniel, Paris, 75014, Franc... More >>e Less <<
NCT01248936 Malignant Melanoma PHASE2 COMPLETED 2025-10-11 Tucson, Arizona, 85724-5078, U... More >>nited States|Los Angeles, California, 90095, United States|San Francisco, California, 94115, United States|San Francisco, California, 94117, United States|Santa Monica, California, 90025, United States|Aurora, Colorado, 80045, United States|New Haven, Connecticut, 06520-8063, United States|Palm Harbor, Florida, 34684, United States|Tampa, Florida, 33612-9497, United States|Atlanta, Georgia, 30322, United States|Park Ridge, Illinois, 60068, United States|Boston, Massachusetts, 02114, United States|Boston, Massachusetts, 02215, United States|Detroit, Michigan, 48201, United States|St. Louis, Missouri, 63110, United States|New York, New York, 10016, United States|New York, New York, 10029, United States|New York, New York, 10032, United States|New York, New York, 10065, United States|Cincinnati, Ohio, 45242, United States|Oklahoma City, Oklahoma, 73104, United States|Portland, Oregon, 97225, United States|Philadelphia, Pennsylvania, 19104, United States|Columbia, South Carolina, 29210, United States|Nashville, Tennessee, 37203, United States|Dallas, Texas, 75246, United States|Richmond, Virginia, 23230, United States|Seattle, Washington, 98195, United States Less <<
NCT01164891 Malignant Melanoma PHASE1 COMPLETED 2025-12-12 Zürich, 8091, Switzerland
NCT01253564 Malignant Melanoma PHASE2 COMPLETED 2012-03-14 CHUV; Departement d'Oncologie,... More >> Lausanne, 1011, Switzerland|Universit?tsspital Zürich; Dermatologische Klinik, Zürich, 8091, Switzerland Less <<
NCT04943198 Histiocytosis PHASE2 RECRUITING 2026-03-30 Mother and Child Institute, Wa... More >>rsaw, Mazovian, 01-211, Poland Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.21mL

2.04mL

1.02mL

20.41mL

4.08mL

2.04mL

References

 

Historical Records

Categories